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ABSTRACT 
 
Type 1 diabetics often experience extreme variations in glucose concentrations which can 
have adverse long- and short-term effects such as severe hypoglycemia, hyperglycemia 
and organ degeneration. Studies have established that there is a need to maintain the 
glucose levels within a normal range (e.g. 80– 150 mg/dL) to avoid complications caused 
by diabetes. However, initial attempts to regulate blood glucose levels using insulin 
infusion pumps, multiple injections or a combination of the two have had limited success 
as they lack the ability to decide the appropriate rate and/or dose of insulin based on the 
current metabolic state of the body.  Consequently, what is needed is an automatic insulin 
delivery system (i.e., artificial pancreas) with the ability to determine continuously the 
rate of insulin delivery required to provide optimum closed-loop glucose control (i.e., to 
minimize the variability around a desired glucose level) and to eliminate the individual 
from the insulin dosage decision making in this control loop. Due to recent advances in 
biomedical technology, such as automatic insulin delivery systems using glucose sensors 
and insulin pumps, blood glucose modeling and control has received considerable 
attention in the process control community and models of various degrees of complexity 
have been developed.  Glucose levels are affected by many variables, such as stress, 
physical activity, hormonal changes, periods of growth, medications, illness/infection, 
fatigue, as well as food intake and insulin tolerance.  Furthermore, not only does glucose 
change from several sources of disturbances but their impact on blood glucose level is 
highly correlated, dynamic and nonlinear making it difficult to distinguish the effect each 
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input has on blood glucose.  Thus, the objective of this research is to introduce a 
modeling methodology that is able to take into account the simultaneous and multiple 
effects of food, activity, stress and their interactions. 
 
The research presented in this thesis is carried out on 15 Type 1 diabetic subjects where 
thirteen variables (i.e., three food variables, seven activity variables, basal insulin, bolus 
insulin, and time of day (TOD)) are collected for two weeks and modeled using the 
Wiener block-oriented model.  Three types of models are compared: input-only (Model 
1), input-output (Model 2), and output-only (Model 3). Results are given for k-steps 
ahead prediction (k-SAP) from 5 minutes to 3 hours in the future and show the 
importance of taking into account the interactions between input variables.  
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CHAPTER 1.  INTRODUCTION 
 
Diabetes mellitus is a chronic metabolic disorder afflicting approximately 220 million 
people worldwide1.  Diabetes affects the way the body uses digested food for growth and 
energy and the exact cause is not known.  However, there are certain contributing factors 
that may lead to the development of diabetes, including genetic factors, obesity, and 
physical inactivity.  Being the third most prevalent disease in the Western world, the 
global health expenditure for diabetes is projected to reach at least 376 billion US dollars 
in 2010 and 490 billion US dollars in 20302.  Diabetes is an incurable condition that can 
be improved through the administration of exogenous insulin.  However, often times the 
patient is not able to mimic the normally occurring insulin profile leading to inadequate 
regulation of blood glucose concentration.  Poor blood glucose regulation can result in 
the deterioration of the proper functioning of various tissues.   
 
1.1 CHARACTERISTICS OF DIABETES MELLITUS 
In normal metabolism, the sugars and starches within digested food are broken down into 
glucose and absorbed into the blood stream, causing a rise in the blood glucose level.  
When the increased blood glucose level is sensed by the pancreatic β-cells they produce 
and secrete insulin directly into the bloodstream.  Insulin is a powerful hormone that 
regulates the uptake of nutrients (i.e., glucose, amino acids and fatty acids) into the cell’s 
interior, where they are broken down into energy by signaling the cell membranes to 
become permeable to these nutrients.  Insulin is also an important aid in the production of 
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storage macromolecules (i.e., protein, glycogen and triglycerides)3.  Diabetes is 
characterized by the inability to synthesize, secrete, or respond to insulin.  There are 
essentially two types of diabetes, which are distinguished by their degree of insulin 
malfunction, Type 1 and Type 2.   
 
Type 2 diabetes mellitus is the most common form of diabetes.  Roughly 90 to 95 percent 
of patients with diabetes have Type 2 diabetes mellitus, which develops predominately in 
adults over the age of 404.  Characterized by the failure of sensitive tissues, such as the 
liver, skeletal muscle and adiposcytes, to respond to insulin, Type 2 diabetics have 
varying degrees of insulin resistance in cells requiring insulin for glucose absorption5.  In 
Type 2 diabetics the pancreas usually produces insulin but the body is unable to use the 
insulin.   
 
Type 1 diabetes, which is also known as insulin-dependent diabetes mellitus or juvenile 
diabetes, is a devastating autoimmune disease where the body’s own immune system 
attacks and destroys the insulin-producing β-cells found in clusters, called islets, in the 
pancreas.  Without this vital hormone, cells and tissues cannot absorb glucose and despite 
high levels of glucose in the bloodstream the patients’ cells can starve to death.  
Therefore, Type 1 diabetics require daily exogenous insulin injections for survival.  This 
exogenous insulin enters the body in the subcutaneous tissue.  A slow, constant or basal 
infusion is used to help the body metabolize glucose in times of fasting, where rapid or 
bolus injections complement the basal and are administered coincidentally with a meal to 
help the body metabolize large loads of carbohydrates (CHO).  As many as three million 
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Americans may have Type 1 diabetes mellitus and several thousand more are diagnosed 
every year, with the majority being under the age of 306.  Although these numbers may 
not be as significant as other disease statistics, the effect of living with an incurable 
disease that is the 6th leading cause of death in the United States is overwhelming7. 
 
1.2 MOTIVATION 
Insulin deficiencies can result in hyperglycemia, the situation when the blood glucose 
level rises much higher than 135 mg/dL for prolonged periods of time.  Hyperglycemia 
can cause damage to many areas of the body over time, increasing the risks of kidney 
failure, blindness, nerve damage, amputations, heart attack, stroke, and can significantly 
decrease a person’s life expectancy.  Hypoglycemia refers to a situation when the blood 
glucose level falls below values of 60 mg/dL.  Hypoglycemia, even for short periods of 
time, can lead to diabetic coma and death.  Thus, maintaining euglycemia, normal blood 
glucose levels, is vital.  Some individuals can manage their disease with meal planning, 
weight control, and regular physical activity.  Others need to routinely take prescription 
medications, such as insulin or oral agents, that either stimulate the body to produce more 
insulin or cause cells to be more responsive to the insulin that is present.  Routine visits to 
a heath care professional for regular HbA1C tests, foot exams, eye exams, and 
immunizations are essential for people with diabetes to help monitor the concentration of 
glucose in their blood and to be alert for the many complications of diabetes.   
 
Even though Type 2 diabetes is more commonly diagnosed in adulthood, is strongly 
associated with overweight and obesity, and disproportionately affects minority 
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populations, both forms of the disease share the same complications.  Because it can 
affect nearly every organ of the body, diabetes is a very complex, serious and costly 
disease.  People with diabetes are more likely to develop other health problems despite 
their vigilant efforts to keep their glucose levels as close to normal as possible.  Chronic 
hyperglycemia damages patients’ organs and can result in the development of life-
threatening disease complications, such as blindness, kidney failure, nerve damage, lower 
limb amputations, heart disease and stroke.  
 
Diabetes is the leading cause of new cases of blindness in adults aged 20-74, responsible 
for eight percent of new blindness cases in the United State8.  People with diabetes are 
also at increased risk for developing glaucoma, cataracts, and corneal disease.  Lower 
limb complications such as amputation, ulcers, and infection are very common in people 
with diabetes.  More than 60 percent of all non-traumatic lower limb amputations occur 
in persons with diagnosed diabetes9, and as many as 50 percent of these patients will have 
another amputation within two to five years of the first8.  Persons with diabetes are the 
fastest growing population receiving kidney dialysis or transplantation.  In patients with 
established kidney problems, hypertension and uncontrolled blood glucose were found to 
be the most important factors contributing to end-stage renal disease progression10.  On 
the flip side, when patients aggressively manage their glucose levels with insulin therapy 
to try to prevent these devastating complications, they are at risk for dangerous episodes 
of hypoglycemia.  Patients may not even be aware that they are experiencing these 
episodes and if left untreated, hypoglycemia can result in coma and even death.  
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All of these complications, when not fatal, can cause disability, financial devastation, 
social dependence, and can reduce a patient’s average life span by many years11.  Given 
the unremitting demands of diabetes, it is not surprising that it heightens the risks for 
various psychiatric disorders, such as depression.  In most cases many of the 
complications can be prevented by appropriate access to medical care, proper diabetes 
education and tight glucose control.  
 
1.3 THE CONTROL PROBLEM  
Glucose levels are affected by many variables, such as stress, physical activity, hormonal 
changes, periods of growth, medications, illness/infection, fatigue, as well as food intake 
and insulin tolerance.  The effect of all these factors on blood glucose concentration is 
highly complex and highly correlated.  In a normal person, several systems, such as the 
metabolic, endocrine, and cardiovascular function collectively to maintain homeostasis.  
However, in a diabetic person their inherent glucose regulation mechanism becomes 
dysfunctional.  
 
The current treatment for Type 1 diabetic patients involves the use of manually controlled 
insulin pumps to administer meal-time insulin boluses, correction insulin boluses, and 
preprogrammed basal insulin infusions, with the insulin dose value either pre-
recommended by a physician or decided by the patient on the basis of invasive finger-
stick measurements of blood glucose.  Essentially, these individuals are serving as their 
own feedback controllers with substantial measurement delays and uncertainties.  Not 
only is this method painful and inconvenient, but it is also unreliable due to the error in 
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estimating the amount of insulin to inject after a meal.  Even with such treatment, Type 1 
diabetics frequently experience serious hypoglycemic and hyperglycemic episodes.  
Consequently, what is needed is an automatic insulin delivery system (i.e., artificial 
pancreas) with the ability to determine continuously the rate of insulin delivery required 
to provide optimum closed-loop glucose control (i.e., to minimize the variability around a 
desired glucose level) and eliminate the individual with Type 1 diabetes from the insulin 
dosage decision making in this control loop.  
 
The development of a closed-loop artificial pancreas has the potential to simultaneously 
reduce the risks of hypoglycemia and hyperglycemia while also enabling individuals with 
Type 1 diabetes mellitus to maintain a normal lifestyle12.  To create a closed-loop 
artificial pancreas three crucial components are needed: a continuous glucose sensor, an 
insulin pump, and a robust controller12-16.  A basic feedback controller would decide the 
best insulin infusion rate based on current deviations from target. More complex 
controllers such as model-based controllers decide the best insulin infusion rate based not 
only on current and past glucose measurements and insulin infusion and meal 
information, but also on model predictions of future glucose trends17.  Although advanced 
control algorithms can provide high performance, they often require a time-consuming 
task of developing a suitable model for the closed-loop control algorithm that is able to 
automatically adjust insulin infusion rates to maintain blood glucose at a desired 
concentration (e.g. 80– 150 mg/dL).  Thus, the development and implementation of an 
accurate model is an important part of an efficient model-based controller.  The diabetes 
process can be viewed as having one output (i.e., blood glucose concentration) and 
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multiple inputs (i.e., carbohydrates, proteins, fats, activity or exercise, energy 
expenditure, stress, and exogenous insulin).  
 
If the amount of carbohydrates in a meal was the only disturbance to blood glucose level, 
management would be easy.  However, not only are there other disturbances in food such 
as fats and proteins but also in the levels and types of activities as well as physical and 
emotional stress.  Furthermore, not only does glucose change from several sources of 
disturbances but their impact on glucose level is highly correlated, dynamic, interactive 
and nonlinear making it difficult to distinguish the effect each input has on blood glucose.  
Thus, it is imperative to account for the interactions between activity and metabolic state 
variables’ and there is strong need for input measurements that can provide information 
such as activity and meals, as well as models that can explicitly deal with interactions.  
 
1.4 ORGANIZATION OF THESIS 
This thesis on multiple disturbance modeling and prediction of blood glucose is 
organized in the following way.  Chapter 2 reviews some of the existing approaches to 
modeling and control of Type 1 diabetes.  Chapter 3 is a paper that is to be submitted to 
Industrial and Engineering Chemistry Research on the multiple input block-oriented 
glucose modeling of 14 Type 1 diabetic subjects. Chapter 4 is a paper that is to be 
submitted to Diabetes Technology that expands on the techniques used in Chapter 3 to 
include model interactions.  Chapter 5 presents conclusions and recommendations for 
future works. 
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CHAPTER 2.  REVIEW OF EXISTING APPROACHES TO 
MODELING AND CONTROL OF GLUCOSE CONCENTRATION 
 
Due to recent advances in biomedical technology, such as automatic insulin delivery 
systems using glucose sensors and insulin pumps, blood glucose modeling and control 
has received considerable attention in the process control community and models of 
various degrees of complexity have been developed.  This chapter is a review of some of 
the existing modeling and control approaches to Type 1 diabetes.  
 
2.1 EXISTING TYPE 1 DIABETES MODELING METHODOLOGIES 
Modeling glucose-insulin interactions has been an active research area and models of 
various degrees of complexity have been developed.  Models can be classified into two 
groups: physiological models and data-based empirical models.   
 
2.1.1 Physiological Models 
Most physiological or compartmental models consist of ordinary differential equations 
that describe the physiology behind the regulatory mechanism of glucose or other 
metabolites.  Physiological models divide the body into several compartments to 
represent the distribution of glucose and/or insulin in the body’s primary organs or 
tissues.  A material balance is written around each compartment, resulting in a set of 
differential equations, which are solved simultaneously.   
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The Bergman Minimal Model (MM) is one the most extensively studied physiological 
model describing glucose-insulin interactions1.  The model was originally proposed to 
interpret plasma glucose and insulin dynamics during an intravenous glucose tolerance 
test (IVGTT) in a non-diabetic person.   In an IVGTT plasma glucose and insulin 
concentrations are sampled after an intravenous glucose injection to determine pancreatic 
islet cell function.   The two compartment Bergman MM for the glucose-insulin system is 
described by three coupled nonlinear ordinary differential equations.  These equations 
along with a few parameters are used to estimate insulin sensitivity (i.e., the capability of 
insulin to increase glucose disposal to the liver, muscles and adipose tissue) and 
pancreatic responsiveness (i.e., the ability of the pancreatic β-cells to secrete insulin in 
response to glucose stimuli). 
 
The Sorenson model is a more extensive six compartment physiological model that 
represents various body organs (i.e., brain, heart/lungs, gut, liver, kidney, and periphery)2.  
The Sorenson model has 19 ordinary differential equations and was originally proposed 
to represent glucose dynamics of a non-diabetic person.  However, by removing the 
insulin release expressions, the model was easily applied to patients with type 1 diabetes.  
Blood glucose regulation is a highly nonlinear and complex process; therefore, most 
physiological models are nonlinear and contain many estimated parameters.  As a result, 
physiological models are generally representative of only an average subject under 
specific disturbance free conditions.  Consequently, physiological models should not be 
used for providing medical advice for a specific individual.   
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2.1.2 Empirical Models 
Empirical models are based on input-output data, and do not provide any insight about 
glucose-insulin dynamics.  Empirical models are also known as black-box models or data 
driven non-parametric models.  They can be developed easily by selecting their structure 
and parameter values by using time series data, and adjusting the parameters for 
describing individual behavior. Such models cannot be used to explain the mechanism of 
a system; however, they can provide good predictions about its future behavior.  Several 
empirical models have been used in the literature including autoregressive moving-
average (ARMA) models, autoregressive moving-average models with exogenous inputs 
(ARMAX), and Wiener networks. 
 
ARMA models form a class of linear time series models that are widely applicable and 
relatively simple in parameterization. 
 
Figure 2.1: Autoregressive moving-average (ARMA) model block diagram. The input, e, is 
the process white noise disturbance variable and it is passed through a linear dynamic block, G(s), 
that has the output, y.   
 
The input, e, of the ARMA model is the process white noise disturbance variable and it is 
passed through a linear dynamic block, G(s), that has the output, y.  The fundamental 
equation of an ARMA (m, n) model has the form:  
  (2.1) 
G(s)
e y
𝜙𝜙(Β𝑚𝑚)𝑦𝑦𝑡𝑡 = 𝜃𝜃(Β𝑛𝑛)𝑒𝑒𝑡𝑡  
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where ϕ(Bm) and θ(Bn) are polynomials of orders m and n, respectively, yt is the measured 
glucose at time t, and et is the error term under the assumptions of independence, 
normality and constant variance (i.e., 𝑒𝑒𝑡~𝑁𝑁(0,𝜎𝜎2)  ∀𝑡𝑡) at time t.   
 
It can be shown that the corresponding differential equation for the ARMA(m, n) model 
for Eq. (2.1) is:  
  (2.2) 
For example, for an ARMA (2, 2) model Eq. (2.2) becomes 
  (2.3) 
The following finite backward difference equations are used to approximate the 
derivatives in Eq. (2.3). 
  (2.4) 
  (2.5) 
To obtain an approximate discrete-time form of Eq. (2.2) the backwards difference 
derivatives in Eqs. (2.4) and (2.5) are substituted into Eq. (2.3) to give 
    (2.6) 
where the following steps show the relationship between Eq. (2.6) and Eq. (2.1). 
𝑑𝑑𝑚𝑚𝑦𝑦(𝑡𝑡)
𝑑𝑑𝑡𝑡𝑚𝑚
+ ⋯+ 𝑑𝑑𝑦𝑦(𝑡𝑡)
𝑑𝑑𝑡𝑡
+ 𝑦𝑦(𝑡𝑡) = 𝑑𝑑𝑛𝑛𝑒𝑒(𝑡𝑡)
𝑑𝑑𝑡𝑡𝑛𝑛
+ ⋯+ 𝑑𝑑𝑒𝑒(𝑡𝑡)
𝑑𝑑𝑡𝑡
+ 𝑒𝑒(𝑡𝑡) 
𝑑𝑑2𝑦𝑦(𝑡𝑡)
𝑑𝑑𝑡𝑡2 + ⋯+ 𝑑𝑑𝑦𝑦(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑦𝑦(𝑡𝑡) = 𝑑𝑑2𝑒𝑒(𝑡𝑡)𝑑𝑑𝑡𝑡2 + ⋯+ 𝑑𝑑𝑒𝑒(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑒𝑒(𝑡𝑡) 
𝑑𝑑2𝑥𝑥(𝑡𝑡)
𝑑𝑑𝑡𝑡2 ≈ 𝑥𝑥𝑡𝑡 − 2𝑥𝑥𝑡𝑡−∆𝑡𝑡 + 𝑥𝑥𝑡𝑡−2∆𝑡𝑡∆𝑡𝑡2  
𝑑𝑑𝑥𝑥(𝑡𝑡)
𝑑𝑑𝑡𝑡
≈
𝑥𝑥𝑡𝑡 − 𝑥𝑥𝑡𝑡−∆𝑡𝑡
∆𝑡𝑡
 
𝑦𝑦𝑡𝑡 − 2𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝑦𝑦𝑡𝑡−2∆𝑡𝑡
∆𝑡𝑡2 + 𝑦𝑦𝑡𝑡 − 𝑦𝑦𝑡𝑡−∆𝑡𝑡∆𝑡𝑡 + 𝑦𝑦𝑡𝑡 ≈ 𝑒𝑒𝑡𝑡 − 𝑒𝑒𝑡𝑡−∆𝑡𝑡 + 𝑒𝑒𝑡𝑡−2∆𝑡𝑡∆𝑡𝑡2 + 𝑒𝑒𝑡𝑡 − 𝑒𝑒𝑡𝑡−∆𝑡𝑡∆𝑡𝑡 + 𝑒𝑒𝑡𝑡  
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  (2.7) 
  (2.8) 
  (2.9) 
  (2.10) 
  (2.11) 
where Bnyt = yt-n∆t, and is called the backwards shift operator.  A number of studies have 
been conducted using an ARMA model to predict future blood glucose concentrations3-4, 
however, the major limitations of this approach is that it dependent only on past outputs 
and linear in both the variables and parameters.  
 
Unlike the ARMA model, the system structure of an ARMAX model includes input 
dynamics.  ARMAX models are useful when dominating disturbances enter the process 
early, such as at the input.  The ARMAX model has more flexibility than the ARMA 
model in handling models that contain disturbances. 
𝑦𝑦𝑡𝑡 − 2𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝑦𝑦𝑡𝑡−2∆𝑡𝑡
∆𝑡𝑡2 + ∆𝑡𝑡𝑦𝑦𝑡𝑡 − ∆𝑡𝑡𝑦𝑦𝑡𝑡−∆𝑡𝑡∆𝑡𝑡2 + ∆𝑡𝑡2𝑦𝑦𝑡𝑡∆𝑡𝑡2
≈
𝑒𝑒𝑡𝑡 − 𝑒𝑒𝑡𝑡−∆𝑡𝑡 + 𝑒𝑒𝑡𝑡−2∆𝑡𝑡
∆𝑡𝑡2 + ∆𝑡𝑡𝑒𝑒𝑡𝑡 − ∆𝑡𝑡𝑒𝑒𝑡𝑡−∆𝑡𝑡∆𝑡𝑡2 + ∆𝑡𝑡2𝑒𝑒𝑡𝑡∆𝑡𝑡2  
(1 + ∆𝑡𝑡 + ∆𝑡𝑡2)𝑦𝑦𝑡𝑡 − (2 + ∆𝑡𝑡)𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝑦𝑦𝑡𝑡−2∆𝑡𝑡= (1 + ∆𝑡𝑡 + ∆𝑡𝑡2)𝑒𝑒𝑡𝑡 − (2 + ∆𝑡𝑡)𝑒𝑒𝑡𝑡−∆𝑡𝑡 + 𝑒𝑒𝑡𝑡−2∆𝑡𝑡  
⟹   𝑦𝑦𝑡𝑡 − 2 + Δ𝑡𝑡1 + Δ𝑡𝑡 + Δ𝑡𝑡2 𝑦𝑦𝑡𝑡−Δ𝑡𝑡 + 11 + Δ𝑡𝑡 + Δ𝑡𝑡2 𝑦𝑦𝑡𝑡−2Δ𝑡𝑡= 𝑒𝑒𝑡𝑡 − 2 + Δ𝑡𝑡1 + Δ𝑡𝑡 + Δ𝑡𝑡2 𝑒𝑒𝑡𝑡−Δ𝑡𝑡 + 11 + Δ𝑡𝑡 + Δ𝑡𝑡2 𝑒𝑒𝑡𝑡−2Δ𝑡𝑡  
⟹   𝑦𝑦𝑡𝑡 − 𝜙𝜙1Β𝑦𝑦𝑡𝑡 + 𝜙𝜙2Β2𝑦𝑦𝑡𝑡 = 𝑒𝑒𝑡𝑡 − 𝜃𝜃1Β𝑒𝑒𝑡𝑡 + 𝜃𝜃2Β2𝑒𝑒𝑡𝑡  
∴   𝜙𝜙(Β2)𝑦𝑦𝑡𝑡 = 𝜃𝜃(Β2)𝑒𝑒𝑡𝑡   
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Figure 2.2: Autoregressive moving-average exogenous input (ARMAX) model block 
diagram. Each input, xi, is passed though their own linear dynamic block, Gi(s), after which they 
are added to produce the output, η. 
 
The inputs, xi, of the ARMAX model are the measured noninvasive variables or 
disturbances.  Each input has its own linear dynamic block, Gi(s), and the output of each 
dynamic block are added to produce the final output, η.  The fundamental expectation 
function of an ARMAX model has the form: 
  (2.12) 
where ηt is the expected value of the glucose concentration at time, t, for i = 1, …, p, and 
δi and ωi are defined below in Eqs. (2.19)-(2.21).  For simplicity, the second order 
differential equation that corresponds to Eq. (2.12) can be shown to be:  
  (2.13) 
where i = 1, . . ., p, p is the total number of inputs, τi is the time constant, ζi is the 
damping coefficient, τai is the lead parameter and Κi is the process gain.  Using the 
G1(s)
x1
ηx2
Gp(s)
xp
G2(s)
+
+
+
𝜂𝜂𝑡𝑡 = 𝛿𝛿1𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝛿𝛿2𝜂𝜂𝑡𝑡−2Δ𝑡𝑡 + 𝜔𝜔1𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝜔𝜔2𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
𝜏𝜏2 𝑑𝑑2𝜂𝜂(𝑡𝑡)
𝑑𝑑𝑡𝑡2 + 2𝜏𝜏𝜏𝜏 𝑑𝑑𝜂𝜂(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝜂𝜂(𝑡𝑡) = Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖 𝑑𝑑𝑥𝑥𝑖𝑖(𝑡𝑡)𝑑𝑑𝑡𝑡 + Κ𝑖𝑖𝑥𝑥𝑖𝑖(𝑡𝑡) 
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backwards difference derivatives from Eqs. (2.4) and (2.5), an approximate form of Eq. 
(2.16) is: 
 (2.14) 
where the following steps show the relationship between Eq. (2.14) and Eq. (2.12). 
  (2.15) 
   (2.16) 
  (2.17) 
  (2.18) 
When comparing Eq. (2.17) to Eq. (2.18) it shows that 
  (2.19) 
  (2.20) 
  (2.21) 
𝜏𝜏2 𝜂𝜂𝑡𝑡 − 2𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝜂𝜂𝑡𝑡−2Δ𝑡𝑡
Δ𝑡𝑡2 + 2𝜏𝜏𝜏𝜏 𝜂𝜂𝑡𝑡 − 𝜂𝜂𝑡𝑡−Δ𝑡𝑡Δ𝑡𝑡 + 𝜂𝜂𝑡𝑡 ≈ Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖 𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 − 𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡Δ𝑡𝑡 + Κ𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡  
𝜏𝜏2 𝜂𝜂𝑡𝑡 − 2𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝜂𝜂𝑡𝑡−2Δ𝑡𝑡
Δt2 + 2𝜏𝜏𝜏𝜏Δt 𝜂𝜂𝑡𝑡 − 𝜂𝜂𝑡𝑡−Δ𝑡𝑡Δt2 + Δ𝑡𝑡2 𝜂𝜂𝑡𝑡Δt2= Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖 Δ𝑡𝑡 𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 − 𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡Δt2 + Κ𝑖𝑖Δt2 𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡Δt2  
(𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2)𝜂𝜂𝑡𝑡 − (2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡)𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝜏𝜏2𝜂𝜂𝑡𝑡−2Δ𝑡𝑡= (Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖 Δ𝑡𝑡 + Κ𝑖𝑖Δ𝑡𝑡2)𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 − Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖Δ𝑡𝑡 𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
⟹   𝜂𝜂𝑡𝑡 − 2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝜏𝜏2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 𝜂𝜂𝑡𝑡−2Δ𝑡𝑡
= ΚiτaiΔt + ΚiΔt2
𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + ΚiτaiΔt𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
∴   𝜂𝜂𝑡𝑡 = 𝛿𝛿1𝜂𝜂𝑡𝑡−Δ𝑡𝑡 + 𝛿𝛿2𝜂𝜂𝑡𝑡−2Δ𝑡𝑡 + 𝜔𝜔1𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝜔𝜔2𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
𝛿𝛿1,𝑖𝑖 = 2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 
𝛿𝛿2,𝑖𝑖 = −𝜏𝜏22𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜔𝜔1,𝑖𝑖 = Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖Δ𝑡𝑡 + Κ𝑖𝑖Δ𝑡𝑡22𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 
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  (2.22) 
Note that, based on Eq. (2.13), the transfer function for an ARMAX (2, 2) model is 
  (2.23) 
This result will be important to illustrate the strength of the Wiener Network after it is 
derived below.  ARMAX models have been proposed by various researchers4-5. However, 
a major limitation of the ARMAX model is its inability to separate the dynamics of 
multiple inputs.  
 
The Wiener network follows a block-oriented model structures formed by a series and/or 
parallel arrangement of nonlinear static and linear dynamic blocks and are commonly 
used in modeling complex nonlinear systems.   A general block diagram with p inputs 
and one output is shown in Figure 2.3. 
 
Figure 2.3: Block diagram for a general Wiener network with p inputs. Each input, xi, is 
passed though their own linear dynamic block, Gi(s), after which they are collected and passed 
through a single nonlinear static gain function, f(V), to produce the output, η. 
 
𝜔𝜔2,𝑖𝑖 = Κ𝑖𝑖𝜏𝜏𝑎𝑎𝑖𝑖Δ𝑡𝑡2𝜏𝜏2 + 2𝜏𝜏𝜏𝜏Δ𝑡𝑡 + Δ𝑡𝑡2 
𝐺𝐺𝑖𝑖(𝑠𝑠) = 𝜂𝜂(𝑠𝑠)𝑋𝑋𝑖𝑖(𝑠𝑠) = Κ𝑖𝑖(𝜏𝜏𝑎𝑎𝑖𝑖𝑠𝑠 + 1)𝜏𝜏2𝑠𝑠2 + 2𝜏𝜏𝜏𝜏𝑠𝑠 + 1 
G1(s)
G2(s)
Gp(s)
f(V)
x1
xp
x2
v1
V η
v2
vp
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The inputs, xi for i = 1,…, p, of the Wiener network are the measured noninvasive 
variables or disturbances.  Each input has its own linear dynamic block, Gi(s), and each 
dynamic block has an intermediate unobservable, output vi which represents the 
independent dynamic response of its corresponding input.  All the intermediate vi’s are 
collected and passed through a nonlinear static gain block, f(V), to produce the final 
output, η.  The fundamental discrete-time equation of the unobservable intermediate vi of 
the Wiener network has the form 
  (2.24) 
δi and ωi are defined below in Eqs. (2.28)-(2.30).  For simplicity, the second order 
differential equation that corresponds to Eq. (2.23) can be shown to be: 
  (2.25) 
Substitution of Eqs. (2.4) and (2.5) into Eq. (2.24) and simplifying gives: 
  (2.26) 
   (2.27) 
Comparing Eq. (2.26) and Eq. (2.27) shows that  
  (2.28) 
𝑣𝑣𝑖𝑖 ,𝑡𝑡 = 𝛿𝛿1,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝛿𝛿2,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡 + 𝜔𝜔1,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝜔𝜔2,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
𝜏𝜏𝑖𝑖
2 𝑑𝑑2𝑣𝑣𝑖𝑖(𝑡𝑡)
𝑑𝑑𝑡𝑡2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖 𝑑𝑑𝑣𝑣𝑖𝑖(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑣𝑣𝑖𝑖(𝑡𝑡) = 𝜏𝜏𝑎𝑎𝑖𝑖 𝑑𝑑𝑥𝑥𝑖𝑖(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑥𝑥𝑖𝑖(𝑡𝑡) 
⟹   𝑣𝑣𝑖𝑖 ,𝑡𝑡 = 2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 𝑣𝑣𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + −𝜏𝜏𝑖𝑖2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 𝑣𝑣𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡
+ 𝜏𝜏𝑎𝑎𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2
𝜏𝜏𝑖𝑖
2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + −𝜏𝜏𝑎𝑎𝑖𝑖Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
∴   𝑣𝑣𝑖𝑖 ,𝑡𝑡 = 𝛿𝛿1,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝛿𝛿2,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡 + 𝜔𝜔1,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−Δ𝑡𝑡 + 𝜔𝜔2,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−2Δ𝑡𝑡  
𝛿𝛿1,𝑖𝑖 = 2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
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  (2.29) 
  (2.30) 
such that ω2,i = 1 - δ1,i - δ2,i - ω1,i. 
 
Here a second-order transfer function for the Wiener network is 
  (2.31) 
such that each input passes through a linear dynamic function with numerator dynamics 
as well as denominator dynamics.  Thus, the strength of the Wiener network over other 
empirical models such as the ARMAX structure is its ability to have more dynamic 
flexibility for each input.  In modeling glucose response, this ability is crucial as it allows 
for different dynamics for carbohydrates and fats, for example. In addition, this allows for 
modeling methodologies to independently determine model parameters for each input.  
Finally, the Wiener structure allows separate development of the static and dynamic 
model parameters.  These characteristics can be exploited to develop powerful modeling 
approaches in ways that are quite unique and advantageous. Studies have been done using 
variations of a Wiener network to monitor the blood glucose concentration of a Type 2 
diabetic6 and blood glucose concentration predictions two hours into the future have been 
shown by a few researchers4,7 in Type 1 diabetics.   
 
 
𝛿𝛿2,𝑖𝑖 = −𝜏𝜏𝑖𝑖2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜔𝜔1,𝑖𝑖 = (𝜏𝜏𝑎𝑎𝑖𝑖 + Δ𝑡𝑡)Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝐺𝐺𝑖𝑖(𝑠𝑠) = 𝑉𝑉𝑖𝑖(𝑠𝑠)𝑋𝑋𝑖𝑖(𝑠𝑠) = (𝜏𝜏𝑎𝑎𝑖𝑖𝑠𝑠 + 1)𝜏𝜏𝑖𝑖2𝑠𝑠2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖𝑠𝑠 + 1 
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2.2 EXISTING TYPE 1 DIABETES CONTROL STRATIGIES 
Several recent studies have considered advanced control techniques like model based 
controllers8-11, robust tracking12, run-to-run control13-14, and the feedforward control for 
carbohydrate content of the meals15 to control glucose. The major limitations of these 
studies is that the control strategies have been developed, tested and successfully 
demonstrated only in simulation (i.e., not using real subjects) and have not proactively 
accounted for the simultaneous effects of food intake, activity, stress and their 
interactions to tightly control glucose. Even the work by Weinzimer et al.16, which 
involved real subjects, was limited to feedback control with food as the only disturbance. 
Though some researchers have tried to account for meal disturbances by taking into 
account the carbohydrate content and take feed forward corrective action8,15, there is no 
approach which currently considers other food nutrients such as fats or proteins. Even 
more critically, disturbances arising from other factors such as activity and stress have 
not been accounted for in any other approach. Thus another major limitation of current 
modeling and control approaches is that they do not account for activity and stress and 
the interactions of activity type variables and metabolic state. While such studies may 
lead to significant advancements in tightening glucose behavior in the years to come, 
accurate anticipatory understanding of the complex effects of food as well as physical 
and emotional activity on blood glucose can pave the way for further tightening of blood 
glucose via feedforward control.  Thus, the objective of this thesis is to present 
advancements by this modeling approach that considers these complexities. 
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3.1 ABSTRACT 
Type 1 diabetics often experience extreme variations in glucose concentrations which can 
have adverse long- and short-term effects such as severe hypoglycemia, hyperglycemia 
and organ degeneration. Studies have established that there is a need to maintain the 
glucose levels within a normal range (e.g. 80– 150 mg/dL) to avoid complications caused 
by diabetes. However, initial attempts to regulate blood glucose levels using insulin 
infusion pumps, multiple injections or a combination of the two have had limited success 
as they lack the ability to decide the appropriate rate and/or dose of insulin based on the 
current metabolic state of the body.  Consequently, what is needed is an automatic insulin 
delivery system (i.e., artificial pancreas) with the ability to determine continuously the 
rate of insulin delivery required to provide optimum closed-loop glucose control (i.e., to 
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minimize the variability around a desired glucose level) and to eliminate the individual 
from the insulin dosage decision making in this control loop.  To create a closed-loop 
artificial pancreas three crucial components are needed: a continuous glucose sensor, an 
insulin pump, and a robust controller1-5.  However, a critical key in the success of the 
artificial pancreas is the ability to effectively model blood glucose concentration (BGC) 
and use this model to improve closed-loop control. Thus, the objective of this paper is to 
introduce a modeling method that takes into account food, activity, and stress in 
developing subject-specific models for Type 1 diabetic subjects.  
 
This paper will present the results on 14 Type 1 diabetic subjects where three food 
variables, seven activity variables, bolus insulin, basal insulin, and time of day (TOD) (a 
total of 13 variables) are collected for two weeks and modeled using the Wiener block-
oriented method of Rollins et al.6.   The method of Rollins et al.6 is modified to use an 
approach that determines dynamic parameters separately from the static parameters such 
that consistency in the fitted model is maintained over all the data sets to guard against 
over-fitting the data. Three types of models are compared: input only (Model 1), input-
output (Model 2), and output only (Model 3). Results are given for k-steps ahead 
prediction (k-SAP) models from 5 minutes to 3 hours in the future.  Results show that 
Model 2 approaches Model 1 as k increases and that this approach can vary considerably 
from subject to subject.  Results also show that Model 3 consistently performs worse than 
Model 1 and Model 2 for large values of k and that this decrease in performance can also 
vary considerably from subject to subject.  
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3.2 INTRODUCTION 
Diabetes is characterized by an inability to synthesize, secrete, or respond to insulin.  
Without this vital hormone, cells and tissues cannot absorb glucose, and the patients’ 
cells can starve to death, despite high levels of glucose in the bloodstream.  Therefore, 
Type 1 diabetics require daily exogenous insulin injections for survival.  However, often 
times the patient is not able to mimic a normally occurring insulin profile which leads to 
inadequate regulation of blood glucose concentration.   
 
The current treatment for Type 1 diabetic patients involves the use of manually controlled 
insulin pumps to administer meal-time insulin boluses, correction insulin boluses, and 
preprogrammed basal insulin infusions, with the insulin dosage either pre-recommended 
by a physician or decided by the patient on the basis of invasive finger-stick 
measurements of blood glucose.  Not only is this method painful and inconvenient, but it 
is also unreliable due to the error in estimating the amount of insulin to inject after a 
meal.  Even with such treatment, Type 1 diabetic frequently experience serious 
hypoglycemic and hyperglycemic episodes.  Consequently, what is needed is an 
automatic insulin delivery system (i.e., artificial pancreas) with the ability to determine 
continuously the rate of insulin delivery required to provide optimum closed-loop glucose 
control (i.e., to minimize the variability around a desired glucose level) and to eliminate 
the individual from the insulin dosage decision making in this control loop.  
 
The development of a closed-loop artificial pancreas has the potential to simultaneously 
reduce the risks of hypoglycemia and hyperglycemia while also enabling individuals with 
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Type 1 diabetes mellitus to maintain a normal lifestyle1.  To create a closed-loop artificial 
pancreas three crucial components are needed: a continuous glucose sensor, an insulin 
pump, and a robust controller1-5.  A basic feedback controller would decide the best 
insulin infusion rate based on current deviations from the target. More complex 
controllers such as model-based controllers decide the best insulin infusion rate based not 
only on past insulin infusion, meal information, current and past glucose measurements, 
but also on model predictions of future glucose trends7.  Although advanced control 
algorithms can provide high performance, they often require a time-consuming task of 
developing a suitable model for the closed-loop control algorithm that is able to 
automatically adjust insulin infusion rates to maintain blood glucose at a desired 
concentration (e.g. 80– 150 mg/dL).  Thus, the development and implementation of an 
accurate model is an important part of a reliable model-based controller.  The human 
glucose process can be viewed as having one output (i.e., blood glucose concentration) 
and multiple inputs (i.e., carbohydrates, proteins, fats, activity or exercise, energy 
expenditure, stress, and exogenous insulin).  The purpose of this article is to evaluate the 
effectiveness of the modeling methodology presented in the following section to infer 
blood glucose concentration from noninvasive input measurements for each subject from 
variables representing food, activity, circadian rhythm, and stress levels. 
 
3.3 MODELING METHODOLOGY  
The modeling approach used in this work is a powerful modification of the Wiener 
method developed by Rollins and Bhandari8 for effectiveness under high input 
correlation.  Wiener modeling follows a block-oriented model structure formed by a 
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series and/or parallel arrangement of nonlinear static and linear dynamic blocks.  A block 
diagram with p inputs and one output is given in Figure 3.1. 
 
Figure 3.1: Block diagram for a general Wiener network with p inputs and one output. Each 
input, xi, is passed though their own linear dynamic block, Gi(s), after which these unobservable 
intermediate outputs are collected and passed through a single nonlinear static gain function, f(V), 
to produce the output, y. 
 
The inputs, xi for i = 1,…, p, of the Wiener network are the measured noninvasive 
variables or disturbances (i.e., food, activity, and stress) and the output, y, is glucose 
concentration.  Each input has its own linear dynamic block, Gi, and each dynamic block 
has an intermediate unobservable, output vi which represents the independent dynamic 
response of its corresponding input.  All the intermediate vi’s are collected and passed 
through a nonlinear static gain block,  f(V), to produce the final output, y.  The linear 
dynamic blocks are essentially linear ordinary differential equations of low order with 
first order input dynamics and usually follow a second-order-plus-lead with dead time 
(SOPLDT) form as shown in Eq. (3.1). 
  (3.1) 
G1
G2
Gp
f (V)
x1
x2
xp
v2
v1
V y
vp
𝜏𝜏𝑖𝑖
2 𝑑𝑑2𝑣𝑣𝑖𝑖(𝑡𝑡)
𝑑𝑑𝑡𝑡2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖 𝑑𝑑𝑣𝑣𝑖𝑖(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑣𝑣𝑖𝑖(𝑡𝑡) = 𝜏𝜏𝑎𝑎𝑖𝑖 𝑑𝑑𝑥𝑥𝑖𝑖(𝑡𝑡 − 𝜃𝜃𝑖𝑖)𝑑𝑑𝑡𝑡 + 𝑥𝑥𝑖𝑖(𝑡𝑡 − 𝜃𝜃𝑖𝑖) 
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where i = 1, . . ., p, p is the total number of inputs, τi is the time constant, ζi is the 
damping coefficient, τai is the lead parameter and θi is the dead time.  Using a backward 
difference approximation (e.g.,
𝑑𝑣𝑖(𝑡)
𝑑𝑡
≈
𝑣𝑖,𝑡−𝑣𝑖,𝑡−∆𝑡
∆𝑡
), applied to a sampling interval of Δt, 
Rollins et al.6 obtained an approximate discrete-time form of Eq. (3.1).   
  (3.2) 
where, to satisfy the unity gain constraint, 𝜔𝜔2,𝑖 = 1 − 𝛿𝛿1,𝑖 − 𝛿𝛿2,𝑖 − 𝜔𝜔1,𝑖 and  
  (3.3) 
  (3.4) 
  (3.5) 
Under the Wiener network, Eqs. (3.3)-(3.5) provide the capability to model the 
independent input effects using free-living data.  The method requires that, for each vi,t, 
the parameters (i.e., δ1,i, δ2,i, ω1,i, ω2,i)  in Eq. (3.2) be determined from the continuous-
time dynamic parameters (i.e., τai, τi, ζi) via Eqs. (3.3)-(3.5).  After obtaining an Eq. (3.2) 
for each i, the modeled glucose value is determined by substituting these results into the 
second order regression form, including interaction terms, of the nonlinear static block 
function, f (V).    
  (3.6) 
  
𝑣𝑣𝑖𝑖 ,𝑡𝑡 = 𝛿𝛿1,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−∆𝑡𝑡 + 𝛿𝛿2,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−2∆𝑡𝑡 + 𝜔𝜔1,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−(∆𝑡𝑡−𝜃𝜃) + 𝜔𝜔2,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−(2∆𝑡𝑡−𝜃𝜃) 
𝛿𝛿1,𝑖𝑖 = 2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝛿𝛿2,𝑖𝑖 = −𝜏𝜏𝑖𝑖2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜔𝜔1,𝑖𝑖 = (𝜏𝜏𝑎𝑎𝑖𝑖 + Δ𝑡𝑡)Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜂𝜂𝑡𝑡 = 𝑓𝑓(𝐕𝐕) = 𝑎𝑎0 + 𝑎𝑎1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡 + 𝑏𝑏1𝑣𝑣1,𝑡𝑡2 + ⋯+ 𝑏𝑏𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡2  +𝑐𝑐1,2𝑣𝑣1,𝑡𝑡𝑣𝑣2,𝑡𝑡 + ⋯+ 𝑐𝑐𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1,𝑡𝑡𝑣𝑣𝑝𝑝 ,𝑡𝑡  
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where ai, bi, and ci,j, denote the linear, quadratic and interaction parameters for i = 1, . . ., 
p-1 and j = 2,…, p.  Thus, the complete input-only model will be generally referred to as 
Model 1 for measured glucose concentration, which includes the error term in additive 
“white” noise, is  
  (3.7) 
where yt is the modeled glucose concentration at time t, αt is the error term under the 
assumptions of independence, normality and constant variance (i.e., 𝑒𝑒𝑡~𝑁𝑁(0,𝜎𝜎2)  ∀𝑡𝑡).  
Under these assumptions Rollins et al.6 proposed the following Model 1 estimator for the 
true value of glucose concentration 
  (3.8) 
  
Under serially correlated noise (Nt) a input-output model or simply referred to as Model 2 
can be derived from  
  (3.9) 
such that Nt is an ARMA (m, n) noise term where 
  (3.10) 
and 
   (3.11) 
  (3.12) 
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝑒𝑒𝑡𝑡  
𝑦𝑦�𝑡𝑡 = ?̂?𝜂𝑡𝑡 = 𝑎𝑎�0 + 𝑎𝑎�1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡 + 𝑏𝑏�1𝑣𝑣1,𝑡𝑡2 + ⋯+ 𝑏𝑏�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡2  +?̂?𝑐1,2𝑣𝑣1,𝑡𝑡𝑣𝑣2,𝑡𝑡 + ⋯+ ?̂?𝑐𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1,𝑡𝑡𝑣𝑣𝑝𝑝 ,𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝑁𝑁𝑡𝑡  
𝑁𝑁𝑡𝑡 = 𝜃𝜃(Β)𝜙𝜙(Β)𝑒𝑒𝑡𝑡  
𝜃𝜃(Β𝑛𝑛) = 1 − 𝜃𝜃1Β1 − 𝜃𝜃2Β2 −⋯− 𝜃𝜃𝑛𝑛Β𝑛𝑛  
𝜙𝜙(Β𝑚𝑚 ) = 1 − 𝜙𝜙1Β1 − 𝜙𝜙2Β2 −⋯−𝜙𝜙𝑚𝑚Β𝑚𝑚  
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where B is the backward shift operator, e.g., Bmyt = yt-mΔt for m = 1, 2,…, and Δt is the 
sampling time.  Let 
   (3.13) 
 Substituting Eqs. (3.10) and (3.13) into Eq. (3.9) gives 
  (3.14) 
Rearranging Eq. (3.14) gives the white noise form  
  (3.15) 
Applying the backward shift operator and rearranging gives 
  (3.13) 
given ϵt = yt – ηt.  Therefore, 
  (3.14) 
Substituting in the backward shift operator gives 
  (3.15) 
Since 1 − 𝜙(Β)
𝜃(Β) = 1 − 𝜋𝜋(Β) = 𝜋𝜋1Β + 𝜋𝜋2Β2 + ⋯  
  (3.16) 
𝜙𝜙(𝛣𝛣𝑚𝑚 )
𝜃𝜃(𝛣𝛣𝑛𝑛) = 𝜋𝜋(Β) = 1 − 𝜋𝜋1Β − 𝜋𝜋2Β2 −⋯ 
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝑒𝑒𝑡𝑡1 − π1Β − π2Β2 −⋯ 
𝑦𝑦𝑡𝑡 − 𝜋𝜋1Β𝑦𝑦𝑡𝑡 − π2Β2𝑦𝑦𝑡𝑡 − ⋯ = 𝜂𝜂𝑡𝑡 − 𝜋𝜋1Β𝜂𝜂𝑡𝑡 − 𝜋𝜋2Β2𝜂𝜂𝑡𝑡 − ⋯+ 𝑒𝑒𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝜋𝜋1(𝑦𝑦𝑡𝑡−Δ𝑡𝑡 − 𝜂𝜂𝑡𝑡−Δ𝑡𝑡) + 𝜋𝜋2(𝑦𝑦𝑡𝑡−2Δ𝑡𝑡 − 𝜂𝜂𝑡𝑡−2Δ𝑡𝑡) + ⋯+ 𝑒𝑒𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝜋𝜋1𝜖𝜖𝑡𝑡−Δ𝑡𝑡 + 𝜋𝜋2𝜖𝜖𝑡𝑡−2Δ𝑡𝑡 + ⋯+ 𝑒𝑒𝑡𝑡 
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + (𝜋𝜋1Β + 𝜋𝜋2Β2 + ⋯ )𝜖𝜖𝑡𝑡 + 𝑒𝑒𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + �1 −𝜙𝜙(Β)𝜃𝜃(Β)� 𝜖𝜖𝑡𝑡 + 𝑒𝑒𝑡𝑡  
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Thus, from Eq. (3.16) the proposed Model 2 one-step ahead prediction (1-SAP) estimator 
for the true value of glucose concentration, yt, is 
  (3.17) 
with 𝜖𝜖?̂? = 𝑦𝑦𝑡 − ?̂?𝜂𝑡 being the Model 1 residual.  Note that the k-step ahead prediction (k-
SAP) model will have a similar structure to the 1-SAP model.  The k-SAP model predicts 
blood glucose concentration at time instant t + k – 1, using Model 1 residuals up to time  
t – Δt, giving the prediction for yt+k-1 as 
   (3.18) 
The complete output-only model or generally referred to as Model 3 for measured 
glucose concentration can be derived from 
  (3.19) 
By substituting Eqs. (3.10) and (3.13) into Eq. (3.19) for Nt gives 
  (3.20) 
Applying the backward shift operator and rearranging gives 
  (3.21) 
Therefore, from Eq. (3.21) the proposed Model 3 1-SAP estimator for the true value of 
glucose concentration, yt, is 
𝑦𝑦�𝑡𝑡 = ?̂?𝜂𝑡𝑡 + �1 − 𝜙𝜙�(Β)𝜃𝜃�(Β)� 𝜖𝜖?̂?𝑡 ≈ ?̂?𝜂𝑡𝑡 + 𝜋𝜋�1𝜖𝜖?̂?𝑡−Δ𝑡𝑡 + 𝜋𝜋�2𝜖𝜖?̂?𝑡−2Δ𝑡𝑡 + ⋯ 
𝑦𝑦�𝑡𝑡+𝑘𝑘−1 = ?̂?𝜂𝑡𝑡+𝑘𝑘−1 + �1 −𝜙𝜙�(Β)𝜃𝜃�(Β)�𝜖𝜖?̂?𝑡 ≈ ?̂?𝜂𝑡𝑡+𝑘𝑘−1 + 𝜋𝜋�1𝜖𝜖?̂?𝑡−Δ𝑡𝑡 + 𝜋𝜋�2𝜖𝜖?̂?𝑡−2Δ𝑡𝑡 + ⋯ 
𝑦𝑦𝑡𝑡 = 𝑁𝑁𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝑒𝑒𝑡𝑡1 − π1Β − π2Β2 −⋯ 
𝑦𝑦𝑡𝑡 = 𝜋𝜋1𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝜋𝜋2𝑦𝑦𝑡𝑡−2∆𝑡𝑡 + ⋯+ 𝑒𝑒𝑡𝑡  
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  (3.22) 
with the k-SAP prediction for yt+k-1 being 
  (3.23) 
3.4 THE STUDY 
Subjects in this study followed a two week free-living protocol in which no constraints 
were placed on their daily diet or lifestyle.  To obtain a sufficiently fast sampling rate 
necessary for discrete-time (DT) dynamic glucose modeling the iProTM Continuous 
Glucose Monitor (Medtronic MiniMed, Inc., Northridge, California) was used to provide 
glucose measurements.  The glucose monitor requires the insertion of a short flexible 
sensor (by needle) into the subcutaneous tissue of the abdominal/supra-iliac area (i.e., 
between the umbilicus and the hip).  Every five minutes the sensor samples the 
surrounding interstitial glucose, which is then used to infer an individual’s blood glucose 
levels. Following FDA recommendations the sensors were replaced every three days.  A 
period of one to two hours of missing measurements resulted during initialization of the 
new sensor after each insertion. To maximize sensor reading accuracy the sensor must be 
calibrated with at least four fingerstick measurements daily from the subject’s personal 
blood glucose lancet meter.  In addition to collecting continuous glucose data the 
subject’s insulin pumps were downloaded on a biweekly basis to retrieve their basal 
insulin infusion rates and daily bolus amounts. 
 
Activity information was collected using the SenseWear® Pro3 Body Monitoring System 
(BodyMedia Inc., Pittsburgh, Pennsylvania) shown in Figure 3.2, which is warn on the 
𝑦𝑦�𝑡𝑡 = 𝜋𝜋�1𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝜋𝜋�2𝑦𝑦𝑡𝑡−2∆𝑡𝑡 + ⋯ 
𝑦𝑦�𝑡𝑡+𝑘𝑘−1 = 𝜋𝜋�1𝑦𝑦𝑡𝑡−∆𝑡𝑡 + 𝜋𝜋�2𝑦𝑦𝑡𝑡−2∆𝑡𝑡 + ⋯ 
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tricep of the subject’s arm.   The SenseWear® armband utilizes pattern detection 
algorithms9,10 that employ physiologic signals from a unique combination of sensors to 
generate values for twenty activity variables. The armband collects data using a two-axis 
accelerometer and four sensors that are used to determine heat flux, skin temperature, 
near body temperature, and galvanic skin response (GSR).  The two-axis accelerometer 
provides information about body position and tracks upper arm movement.  The heat flux 
sensor calculates the amount of heat being dissipated from the body by measuring the 
amount of heat lost along a thermally conductive path between the skin and a vent on the 
side of the armband.  Skin temperature and near-body temperature are measured by 
sensitive thermistors and GSR is measured via the conductivity of the subject’s skin as it 
varies due to physical and emotional stimuli10.  The SenseWear® armband samples at a 
rate of one sample per minute, however, measurements at five minute intervals were used 
to match the sampling rate of the glucose monitor.  The armband was typically only 
removed once a day while the subject was showering.  
 
Figure 3.2: BodyMedia, Inc. SenseWear® Pro3 Body Monitoring System 
 
 
Timestamp Button
2-axis Accelerometer 
(inside)
Heat Flux Sensor
Near-Body Temperature
GSR Sensors
Skin Temperature
AAA Battery, USB connector 
and wireless inside
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Food information was collected two ways during this study: (a) detailed food logs and (b) 
timestamping on the armband.  As part of protocol (a) subjects recorded the approximate 
serving size and the time they started eating for all of the food they consumed into a 
PDA, which used Weightmania® Pro software (Edward A. Greenwood, Inc., Cambridge, 
Massachusetts) to determine the carbohydrate, fat, and protein content of their meals.  As 
part of protocol (b) the subjects repeated the study following a timestamping protocol, 
which used the timestamp feature on the SenseWear® armband, to indicate the 
approximate size of the meal and the time they started eating.  In addition, the subject’s 
insulin pumps were downloaded to retrieve their daily bolus and basal insulin infusion 
rates. 
 
The objective of this modeling problem is to maximize the true but unknown correlation 
coefficient between the observed and fitted glucose concentrations, which is defined as 
𝜌𝑦,𝑦�  and estimated by rfit.  Under this objective a model is useful only when the true 
correlation of the fitted model is greater than zero (i.e., 𝜌𝑦,𝑦� > 0) and more specifically, 
the closer this value is to the upper limit of one (1), the more useful the model.  As 
described in Rollins et al.6, due to the highly complex mapping of the parameters into the 
response space of rfit, the following indirect criterion is used 
  (3.24) 
  
𝑀𝑀𝑎𝑎𝑥𝑥𝑖𝑖𝑚𝑚𝑖𝑖𝑧𝑧𝑒𝑒 𝑟𝑟𝑓𝑓𝑖𝑖𝑡𝑡  𝑏𝑏𝑦𝑦 𝑀𝑀𝑖𝑖𝑛𝑛𝑖𝑖𝑚𝑚𝑖𝑖𝑧𝑧𝑖𝑖𝑛𝑛𝑔𝑔     𝑆𝑆𝑆𝑆𝐸𝐸Θ = � (𝑦𝑦1 − 𝑦𝑦�𝑡𝑡)2𝑛𝑛Δ𝑡𝑡
𝑡𝑡=Δ𝑡𝑡  
 𝑆𝑆𝑢𝑢𝑏𝑏𝑗𝑗𝑒𝑒𝑐𝑐𝑡𝑡 𝑡𝑡𝑜𝑜:                                         𝜏𝜏𝑖𝑖 > 0,  𝜏𝜏𝑖𝑖 > 0,  𝜃𝜃𝑖𝑖 ≥ 0   ∀𝑖𝑖 
37 
 
 
where Θ is a vector representing the estimated dynamic and static parameters, ζi, τi, τai, 
and θi, for all i.  Therefore, to achieve this objective this work seeks to identify a reduced 
nonlinear static structure of Eq. (3.6) that results in a sufficiently large value of rfit.  
Based on results in Rollins et al.6 for a Type 2 subject and in Beverlin et al.11 for 20 non-
insulin dependent Type 2 diabetics, a goal was set for rfit to be greater than 0.40 with a 
value greater than 0.60 considered excellent.  
 
This work uses the reduced model in Eq. (3.25) to infer blood glucose concentration.  Eq. 
(3.25) eliminates all second order and interaction terms of Eq. (3.6) and consists only of 
the linear, a, terms. 
  (3.25)  
To protect against over fitting, the modeling approach involves dividing the data into 
three types of data sets: training, validation, and test.  The first half of this study involved 
splitting the data into a week of training data and a week of validation data.  Data in the 
training set were used to directly determine the model parameters and hence, obtain the 
value of the optimization criterion.  Data in the validation set are used to guard against 
over fitting and to evaluate the model against data that were not directly used by the 
optimization process to estimate the model parameters.  While none of the data of the 
validation set are used in the objective function, the model performance on this data set is 
used to control the direction and progress of the model towards optimality.  In the second 
half of the study the data was split into a week of training data, four days of validation 
data, and three days of test data.  In this portion of the study the test data had no influence 
?̂?𝜂𝑡𝑡 = 𝑓𝑓(𝐕𝐕) = 𝑎𝑎�0 + 𝑎𝑎�1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡  
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on the fit of the model and was only used to evaluate the model after the optimization 
process was complete.   
 
Using the Wiener network given by Eqs. (3.1)-(3.5) and Eq. (3.25), a procedure was 
developed that can accurately estimate the 3p dynamic parameters and the p+1 static 
parameters even when the number of sampling times (n) is much less the total number of 
dynamic and static parameters. This procedure requires each input to have a separate set 
of dynamic parameters, which is a requirement satisfied by the Wiener network but not 
other common networks like the autoregressive moving-average exogenous input 
(ARMAX) model.  Separate estimation of the dynamic parameters for each input is 
possible by the result that rfit for a simple linear regression model is a function of the 
explanatory variable only12. More specifically, rfit for the model given in Eq. (3.26) 
depends only on the dynamic parameters τi, ζi and τai associated with input i. 
  (3.26) 
Therefore, the proposed model identification procedure estimates the dynamic parameters 
for each input using Eq. (3.26), one input at a time. After obtaining dynamic parameters 
for each input that gives rfit values that are similar in both training and validation sets the 
dynamic parameter values are fixed and the static parameters in Eq. (3.25) are estimated  
using the Excel® Solver Routine.   
 
While correlation is one method used in this study for assessing the usefulness of the 
model, three other statistics were also used to assess how well a model fits.  These 
𝑦𝑦𝑡𝑡 = 𝑎𝑎0 + 𝑎𝑎𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡 + 𝑒𝑒𝑡𝑡  
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statistics are the absolute error (AE), average absolute error (AAE) and relative average 
absolute error (RAAE).  The AE is simply the average of the residuals.  
  (3.27) 
where n is the number of observed blood glucose measurements in the statistic being 
calculated.  A check that the aforementioned convergence criterion was met was the AE 
value equaling 0.0 mg/dL.  A model with a significantly large absolute value of AE is an 
indication of model bias.  The AAE of a model is similar to the AE of a model except the 
AAE takes the absolute value of the residuals before finding the average.  
  (3.28) 
In addition to sufficiently large rfit values for both the training and validation/testing sets 
an acceptable model must also have a relatively small AAE that is close to zero.  Hence, 
accuracy is expected to increase as AAE decreases.   
 
Since a large amount of variability in blood glucose concentration between subjects is 
common the RAAE is a statistic used to scale the AAE and thus tends to be a better judge 
of model accuracy than the AAE.  The RAAE of a model is determined by dividing the 
AAE by the standard deviation of the measured blood glucose concentration.  
  (3.29) 
𝐴𝐴𝐸𝐸 = 1
𝑛𝑛
�(𝑦𝑦𝑖𝑖 − 𝑦𝑦�𝑖𝑖)𝑛𝑛
𝑖𝑖=1  
𝐴𝐴𝐴𝐴𝐸𝐸 = 1
𝑛𝑛
�|𝑦𝑦𝑖𝑖 − 𝑦𝑦�𝑖𝑖 |𝑛𝑛
𝑖𝑖=1  
𝑅𝑅𝐴𝐴𝐴𝐴𝐸𝐸 = 𝐴𝐴𝐴𝐴𝐸𝐸
𝑠𝑠𝑡𝑡𝑑𝑑𝑒𝑒𝑣𝑣(𝑦𝑦𝑖𝑖) 
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where 𝑠𝑠𝑡𝑡𝑑𝑑𝑒𝑒𝑣𝑣(𝑦𝑦𝑖) = � 1𝑛−1∑ (𝑦𝑦𝑖 − 𝑦𝑦�𝑖)2𝑛𝑖=1 .  Like AAE an acceptable model must have a 
relatively small RAAE and the accuracy of a model is expected to increase as RAAE 
decreases.  A study in Rollins et al.6 determined that for replicated glucose meter lancet 
measurements RAAE for the validation set was roughly 0.60, this result will be used as a 
benchmark for determining model performance in this study.   
 
3.5 RESULTS AND DISCUSSION 
The first set of results presented is for the case consisting of one week of training and one 
week of validation and are given for the reduced Model 1 under Eq. (3.25).  Subjects that 
followed the detailed food logging protocol are denoted with an “a” and subjects that 
followed the armband timestamping protocol are denoted with a “b”.  Subjects without an 
“a” or “b” only completed the detailed food logging protocol study.  Table 3.1 shows that 
for all subjects the training AE value was 0.0 mg/dL, validating that the convergence 
criterion was met.  The AAE value for all the subjects approximately averaged 43.7 
mg/dL and 48.3 mg/dL in training and validation, respectively.  The slight difference 
between the two sets can be attributed to bias in the validation set.  Evidence of this bias 
is seen in the mean AE value of 6 mg/dL.  The amount of bias in the validation set is 
subject specific and is shown to give AE values as small as -0.92 mg/dL for Subject 5 to 
as large as 37 mg/dL for Subject 2b.   
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Table 3.1: Model 1 training/validation modeling values. Results are for two weeks of data 
divided into one week of training and one week of validation. AE and AAE values are presented 
in mg/dL. 
 
 
The training and validation average RAAE values are 0.37 and 0.38, respectively, which 
are considerably better than the target of 0.6.  The validation RAAE value of 0.62 for 
Subject 4b is the only case when the RAAE exceeded that of the repeated lancet values 
and even then it was only a minor increase.  Average training and validation rfit values are 
0.58 and 0.60, respectively, which is at the point where Beverlin et al.11 considered rfit to 
be exceptional.  In addition, it is important to note that on average only about a 0.04 drop 
in correlation was observed in the cases that followed the armband timestamping protocol 
suggesting that the reduction food information had little impact on the predictive ability 
of the model.  
 
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.00 33.66 0.23 0.72 -24.33 47.22 0.43 0.79
1b 0.00 47.40 0.30 0.57 13.99 46.77 0.30 0.73
2a 0.00 44.83 0.44 0.61 20.41 50.45 0.33 0.68
2b 0.00 46.66 0.43 0.69 37.06 56.48 0.36 0.64
3a 0.00 31.64 0.38 0.53 33.43 48.36 0.39 0.55
3b 0.00 34.09 0.38 0.36 11.37 44.22 0.44 0.47
4a 0.00 62.60 0.47 0.56 15.12 73.64 0.53 0.55
4b 0.00 51.85 0.37 0.63 -35.17 64.16 0.62 0.56
5 0.00 24.66 0.22 0.59 -0.92 26.28 0.24 0.56
6 0.00 43.64 0.34 0.41 12.27 36.11 0.25 0.42
7 0.00 65.90 0.55 0.61 -18.06 60.98 0.59 0.63
8 0.00 50.56 0.38 0.64 -12.10 54.77 0.36 0.61
9 0.00 50.05 0.31 0.67 24.93 45.63 0.23 0.68
10 0.00 24.60 0.33 0.56 6.70 18.73 0.23 0.58
Mean 0.00 43.72 0.37 0.58 6.05 48.13 0.38 0.60
Stdev 0.00 12.69 0.09 0.10 21.60 14.42 0.13 0.10
1 week Validation1 week Training
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The second set of results, which are presented in Table 3.2, are for the reduced Model 1 
under Eq. (3.25) for one week of training, four days of validation and three days of 
testing.  For this data set the average rfit for the training and test set was 0.58 and was 0.59 
for the validation set. Since the model was able to perform equally as well on the test set 
as in the training and validation set there is evidence to believe that the model 
development algorithm used in this paper is useful for predicting blood glucose 
concentrations on data sets that have no influence on the model.   
 
Table 3.2: Training/Validation/Testing Model 1 modeling values. Results for two weeks of 
data divided into one week of training, four days of validation and 3 days of testing. AE and AAE 
values are presented in mg/dL. 
 
 
To assess the contribution of the armband for modeling Type 1 diabetes, Table 3.3 
presents the percent contribution of food, armband, insulin and TOD to the final reduced 
Model 1.  As an example, the percent contribution of food for the reduced Model 1 was 
calculated using Eq. (3.30).  
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.00 30.37 0.21 0.79 -22.29 41.76 0.36 0.81 -25.26 60.82 0.56 0.63
1b 0.00 44.88 0.29 0.62 15.03 43.61 0.25 0.68 0.83 50.87 0.37 0.70
2a 0.00 45.04 0.45 0.60 20.13 52.86 0.36 0.66 16.70 46.87 0.30 0.66
2b 0.00 56.36 0.53 0.56 25.63 52.59 0.32 0.58 -1.74 58.71 0.48 0.56
3a 0.00 31.93 0.38 0.53 31.13 52.47 0.45 0.52 35.35 40.47 0.29 0.57
3b 0.00 33.55 0.37 0.39 23.84 42.92 0.36 0.47 -4.61 45.51 0.55 0.48
4a 0.00 63.33 0.48 0.55 31.37 87.31 0.63 0.54 -15.01 55.85 0.44 0.67
4b 0.00 53.16 0.38 0.61 -19.44 51.80 0.41 0.65 -54.90 75.82 0.90 0.55
5 0.00 25.04 0.22 0.59 0.30 29.39 0.26 0.58 -8.24 25.77 0.25 0.38
6 0.00 43.50 0.34 0.41 16.91 39.35 0.26 0.41 8.05 32.32 0.24 0.46
7 0.00 67.23 0.55 0.57 -33.34 62.55 0.74 0.67 2.87 64.80 0.47 0.54
8 0.00 50.93 0.39 0.64 -12.89 60.71 0.37 0.53 -21.29 53.04 0.37 0.68
9 0.00 52.77 0.33 0.65 37.91 59.76 0.29 0.60 -0.07 34.05 0.20 0.60
Mean 0.00 46.01 0.38 0.58 8.79 52.08 0.39 0.59 -5.18 49.61 0.42 0.58
Stdev 0.00 12.99 0.10 0.10 23.59 14.22 0.15 0.10 21.75 14.13 0.19 0.10
1 week Training 4 day Validation 3 day Test
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  (3.30) 
where Cfood, Carmband, Cinsulin, and CTOD is the average contribution of food, armband, 
insulin, and TOD, respectively.  The contribution for food, for example, is determined by 
  (3.31) 
The percent contribution of the armband for all the subjects averaged approximately 
45.5%.  As seen in Table 3.3 the amount the armband contributes to the model is subject 
specific and is shown to contribute as little as 5.9% for Subject 3a to as much as 87.3% 
for Subject 1a.  Another important result to note is how the contribution of food drops 
when a subject follows the armband timestamping protocol for food logging rather than 
the detailed food logging protocol.  This result suggests that while the timestamping 
protocol is a more efficient way to collect food information it results in a loss of food 
information.  However, since the change in food logging procedure does not prove to 
have a significant effect on model performance the amount of useful information is being 
made up for in one or more of the other inputs.  The loss in food information was 
generally made up for by the armband, as evident by the 29% increase in average 
armband contribution for subjects following the timestamping protocol. 
% 𝐶𝐶𝑓𝑓𝑜𝑜𝑜𝑜𝑑𝑑 = 𝐶𝐶𝑓𝑓𝑜𝑜𝑜𝑜𝑑𝑑𝐶𝐶𝑓𝑓𝑜𝑜𝑜𝑜𝑑𝑑 + 𝐶𝐶𝑎𝑎𝑟𝑟𝑚𝑚𝑏𝑏𝑎𝑎𝑛𝑛𝑑𝑑 + 𝐶𝐶𝑖𝑖𝑛𝑛𝑠𝑠𝑢𝑢𝑙𝑙𝑖𝑖𝑛𝑛 + 𝐶𝐶𝑇𝑇𝑂𝑂𝐷𝐷 𝑥𝑥100 
𝐶𝐶𝑓𝑓𝑜𝑜𝑜𝑜𝑑𝑑 = |𝛽𝛽1𝑣𝑣1 + 𝛽𝛽2𝑣𝑣2 + 𝛽𝛽3𝑣𝑣3| 
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Table 3.3: Percent contribution of inputs in Model 1. 
 
 
The final portion of this study examined the value of the proposed modeling approach for 
k-SAP.  The advantage of using Model 2 in k-SAP is that Model 2 incorporates both 
inputs and outputs to predict future values of blood glucose concentration while Model 1 
only uses inputs and Model 3 is an output-only model.  As shown in Figure 3.3 the 
validation rfit decreases as k increases for both Model 2 and Model 3.  Model 3 drops off 
quickly indicating that while an output-only model can aid in prediction when the number 
of steps ahead is small, it can also degrade quickly as k increases.  As seen in Figure 3.3 
the rate in performance degradation for both Model 2 and Model 3 can vary considerably 
from subject to subject.  However, the performance of Model 2 may only be slightly 
worse than that of Model 1 in rare cases due to lack of fit cause by the residual model 
part of Model 2.  Figure 3.4 includes plots of Subject 1a one week validation set for: (a) 
Subject Food Armband Insulin TOD
1a 10.62 40.80 48.58 0.00
1b 2.61 87.26 10.13 0.00
2a 12.61 36.84 31.66 18.89
2b 9.62 14.50 61.90 13.97
3a 0.94 5.88 93.19 0.00
3b 10.64 69.32 20.04 0.00
4a 3.85 41.50 54.65 0.00
4b 0.69 70.80 25.80 2.71
5 7.95 47.02 41.05 3.98
6 16.83 45.29 37.88 0.00
7 24.03 31.89 25.77 18.31
8 24.52 50.23 23.94 1.31
9 13.59 41.07 38.40 6.94
10 5.45 54.14 19.65 20.76
Mean 10.28 45.47 38.05 6.21
Stdev 7.65 21.30 21.46 8.10
% Contribution
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Model 1, (b) 1-SAP Model 2, (c) 6-SAP Model 2, (d) 12-SAP Model 2, (e) 18-SAP 
Model 2 and (f) 36-SAP Model 2.  The figure illustrates the ability of the k-SAP model to 
correct for model bias and how this corrective ability decreases as k increases. Additional 
modeling results for k-SAP have been tabulated and can be found in Appendices 3.1-3.4. 
 
 
Figure 3.3: Relationship between validation rfit and k for two Type 1 diabetic subjects. (a) 
Subject 1a (b) Subject 9  
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Figure 3.4: Subject 1a linear and k-step ahead prediction model comparison. Results are 
shown for a week of validation. (a) Model fit under Model 1. (b) Model fit under Model 2 for 1-
step ahead prediction. (c) Model fit under Model 2 for 6-step ahead prediction. (d) Model fit 
under Model 2 for 12-step ahead prediction. (e) Model fit under Model 2 for 18-step ahead 
prediction. (f) Model fit under Model 2 for 36-step ahead prediction. 
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3.6 CONCLUDING REMARKS 
In this study the convergence criterion was met and the set of model parameters found 
through the optimization process proved to be effective in maintain a stable model 
throughout the training, validation, and test sets.  Results showed that the reduced 
nonlinear static model generated rfit values significantly greater than those found for 20 
Type 2 diabetics.  It is believed that this significant increase in model performance can be 
attributed to the inclusion of insulin in the model.  It should be noted that there was little 
difference in model performance as it relates to the reduction food information from the 
detailed food logging protocol to the armband timestamping protocol.  While 
timestamping is much more desirable for subjects due to the lack of effort necessary to 
maintain an accurate food log there is concern as to whether it will provide accurate 
enough information to be useful in Type 1 diabetes control.  
 
This study also presented a compelling case for the inclusion of the armband in glucose 
modeling for Type 1 diabetics.  It was shown that the reduction of food information that 
occurred during the timestamping protocol was more often made up for by the armband 
rather than insulin and time of day.  The final portion of this first study examined the 
value of the proposed modeling approach for k-SAP and showed its ability to effectively 
correct for model bias for a short time into the future.  
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3.9 APPENDIX 3.1:  Training/Validation Model 2 k-SAP Tables  
Table 3.4: Model 2 training/validation for 1-SAP modeling. Results are for two weeks of data 
divided into one week of training and one week of validation. AE and AAE values are presented 
in mg/dL.  *Modeling results for Subject 10 are for one week of data that was divided into three 
days of training and four days of validation. 
 
1 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.01 4.63 0.03 0.99 -0.56 4.31 0.03 1.00
1b -0.02 4.11 0.02 1.00 0.15 4.53 0.03 1.00
2a -0.05 4.08 0.03 0.99 0.30 4.69 0.03 0.99
2b 0.00 3.89 0.03 1.00 0.55 4.67 0.03 0.99
3a -0.04 4.16 0.05 0.99 0.85 4.20 0.04 1.00
3b 0.00 3.12 0.03 1.00 0.23 5.43 0.05 0.99
4a 0.01 5.84 0.03 0.99 0.21 5.85 0.04 1.00
4b 0.03 5.14 0.03 1.00 -0.45 5.29 0.04 0.99
5 -0.03 2.34 0.02 1.00 -0.02 2.62 0.02 0.99
6 -0.03 4.69 0.04 0.99 0.25 5.10 0.04 0.99
7 0.02 6.27 0.04 0.99 0.04 7.72 0.05 0.99
8 0.07 4.81 0.03 1.00 -0.18 4.64 0.03 0.99
9 0.01 3.27 0.02 1.00 0.27 2.93 0.02 1.00
10 0.02 2.61 0.03 0.99 0.09 2.85 0.04 0.99
Mean 0.00 4.21 0.03 0.99 0.12 4.63 0.03 0.99
Stdev 0.03 1.14 0.01 0.00 0.36 1.32 0.01 0.00
Training Validation
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Table 3.5: Model 2 training/validation for 6-step ahead prediction modeling. Results are for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
6 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.01 18.36 0.13 0.92 -4.20 18.07 0.14 0.96
1b -0.21 18.63 0.12 0.94 1.52 20.57 0.13 0.94
2a -0.33 17.42 0.15 0.94 2.72 18.07 0.11 0.94
2b -0.02 18.91 0.17 0.94 5.41 19.50 0.13 0.93
3a -0.51 17.16 0.21 0.88 7.20 20.71 0.18 0.90
3b -0.05 14.91 0.16 0.90 2.33 20.66 0.18 0.87
4a -0.03 24.87 0.16 0.93 2.13 26.06 0.17 0.95
4b 0.12 19.53 0.12 0.95 -4.14 23.07 0.17 0.93
5 -0.27 12.90 0.11 0.89 -0.12 14.08 0.13 0.88
6 -0.34 18.15 0.15 0.90 1.77 20.70 0.15 0.83
7 0.46 24.77 0.18 0.95 0.01 24.47 0.19 0.94
8 0.57 22.11 0.17 0.93 -1.49 21.63 0.14 0.91
9 0.25 16.90 0.10 0.95 3.08 14.24 0.08 0.96
10 -0.06 10.47 0.14 0.93 0.88 10.61 0.14 0.87
Mean -0.03 18.22 0.15 0.93 1.22 19.46 0.15 0.91
Stdev 0.31 4.00 0.03 0.02 3.17 4.21 0.03 0.04
Training Validation
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Table 3.6: Model 2 training/validation for 12-step ahead prediction modeling. Results are for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
12 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a -0.25 25.93 0.18 0.84 -8.46 26.92 0.22 0.91
1b -0.50 27.87 0.17 0.86 3.75 30.25 0.19 0.87
2a -0.86 27.29 0.25 0.86 5.77 26.44 0.17 0.89
2b -0.16 30.46 0.27 0.86 12.39 29.81 0.19 0.86
3a -1.14 24.34 0.30 0.75 13.44 32.42 0.29 0.75
3b -0.06 22.29 0.24 0.77 4.47 28.27 0.26 0.78
4a 0.15 39.38 0.28 0.83 5.23 42.00 0.30 0.87
4b 0.03 30.69 0.20 0.87 -8.60 37.16 0.30 0.83
5 -0.39 20.54 0.18 0.72 -0.16 22.05 0.20 0.71
6 -0.90 27.45 0.23 0.79 3.94 29.30 0.21 0.68
7 0.96 36.31 0.28 0.89 -0.77 35.22 0.29 0.87
8 0.62 32.64 0.25 0.86 -3.05 33.08 0.21 0.80
9 0.97 29.64 0.18 0.87 7.07 23.78 0.13 0.89
10 -0.03 16.34 0.21 0.82 2.11 14.80 0.19 0.73
Mean -0.11 27.94 0.23 0.83 2.65 29.39 0.23 0.82
Stdev 0.65 6.07 0.04 0.05 6.54 6.74 0.05 0.07
Training Validation
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Table 3.7: Model 2 training/validation for 18-step ahead prediction modeling. Results are for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
18 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.04 29.92 0.21 0.78 -11.85 32.63 0.28 0.88
1b -0.97 34.18 0.22 0.79 6.14 36.55 0.22 0.82
2a -1.18 34.19 0.34 0.77 8.60 33.68 0.22 0.84
2b -0.29 37.83 0.34 0.80 18.83 36.96 0.24 0.81
3a -1.58 26.62 0.33 0.67 17.93 38.71 0.34 0.64
3b 0.02 26.34 0.28 0.66 6.19 33.20 0.31 0.71
4a 0.47 49.74 0.37 0.74 7.97 54.90 0.41 0.79
4b -0.45 38.12 0.26 0.81 -12.34 46.95 0.40 0.73
5 -0.33 22.94 0.20 0.63 -0.33 25.50 0.23 0.61
6 -1.40 32.01 0.27 0.71 5.65 34.89 0.25 0.52
7 0.86 43.26 0.34 0.85 -1.38 43.88 0.37 0.79
8 0.39 37.87 0.29 0.80 -5.00 39.53 0.26 0.73
9 1.64 38.26 0.23 0.80 10.87 30.72 0.16 0.82
10 -0.06 19.97 0.26 0.72 3.37 16.44 0.21 0.65
Mean -0.20 33.66 0.28 0.75 3.91 36.04 0.28 0.74
Stdev 0.90 8.08 0.05 0.07 9.44 9.23 0.08 0.10
Training Validation
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Table 3.8.: Model 2 training/validation for 36-step ahead prediction modeling. Results are 
for two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
  
36 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.92 33.95 0.24 0.72 -19.73 43.07 0.38 0.82
1b -1.98 44.18 0.29 0.61 12.79 47.52 0.29 0.70
2a -1.14 42.67 0.44 0.65 13.88 45.32 0.31 0.73
2b -0.50 46.93 0.43 0.71 29.00 47.71 0.31 0.73
3a -2.64 29.75 0.37 0.53 28.89 46.59 0.38 0.54
3b 0.65 32.26 0.35 0.47 9.99 42.04 0.40 0.55
4a 1.90 60.73 0.47 0.63 14.55 71.39 0.54 0.64
4b -2.12 46.62 0.33 0.69 -26.66 59.32 0.58 0.57
5 -1.05 23.43 0.21 0.58 -0.02 26.68 0.24 0.55
6 -3.75 37.66 0.32 0.57 7.72 38.47 0.27 0.38
7 -0.09 55.87 0.47 0.74 -0.79 56.10 0.49 0.65
8 -0.33 46.54 0.35 0.68 -9.73 48.71 0.31 0.61
9 3.01 48.49 0.29 0.71 16.39 40.64 0.21 0.68
10 0.19 24.39 0.32 0.59 7.49 18.92 0.23 0.54
Mean -0.50 40.96 0.35 0.64 5.98 45.18 0.35 0.62
Stdev 1.81 11.18 0.08 0.08 16.22 12.84 0.12 0.11
Training Validation
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3.10 APPENDIX 3.2:  Training/Validation Model 3 k-SAP Tables 
Table 3.9: Model 3 training/validation for 1-step ahead prediction modeling. Results are for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
1 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.28 3.50 0.02 0.99 0.32 2.70 0.02 1.00
1b 0.20 2.78 0.02 1.00 0.22 3.55 0.02 1.00
2a 0.19 2.80 0.02 1.00 0.26 3.37 0.02 1.00
2b 0.27 3.67 0.03 1.00 0.30 4.12 0.03 1.00
3a -0.05 3.83 0.05 0.99 0.82 3.80 0.03 1.00
3b 0.20 2.67 0.03 1.00 0.29 5.35 0.05 0.99
4a 0.33 5.65 0.03 0.99 0.31 5.44 0.03 1.00
4b 0.26 4.45 0.03 1.00 0.20 4.47 0.03 1.00
5 0.15 2.28 0.02 1.00 0.17 2.45 0.02 0.99
6 0.26 4.20 0.03 0.99 0.32 4.58 0.03 0.99
7 0.32 4.92 0.04 1.00 0.49 6.61 0.05 0.99
8 0.32 4.64 0.03 1.00 0.35 4.45 0.03 1.00
9 0.19 3.15 0.02 1.00 0.17 2.84 0.02 1.00
10 0.14 2.29 0.03 1.00 0.12 2.74 0.04 0.99
Mean 0.22 3.63 0.03 1.00 0.31 4.03 0.03 0.99
Stdev 0.10 1.04 0.01 0.00 0.17 1.21 0.01 0.00
Training Validation
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Table 3.10: Model 3 training/validation for 6-step ahead prediction modeling. Results are for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
6 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 2.85 19.90 0.14 0.90 3.65 17.15 0.12 0.95
1b 2.64 18.91 0.11 0.94 2.69 23.67 0.14 0.92
2a 2.48 14.91 0.12 0.95 3.35 16.92 0.11 0.94
2b 2.88 20.12 0.17 0.94 3.48 19.34 0.12 0.93
3a 2.95 16.99 0.20 0.87 4.70 20.88 0.18 0.89
3b 2.44 14.84 0.15 0.91 3.55 22.01 0.19 0.85
4a 3.29 24.76 0.15 0.93 3.35 25.68 0.16 0.94
4b 2.53 18.38 0.11 0.95 2.05 20.40 0.14 0.93
5 1.86 13.53 0.11 0.89 2.18 14.70 0.13 0.87
6 2.37 17.19 0.13 0.91 2.60 20.91 0.15 0.83
7 2.92 21.11 0.15 0.96 3.81 24.48 0.18 0.93
8 3.20 23.48 0.17 0.93 3.72 22.67 0.14 0.90
9 2.14 17.20 0.10 0.95 1.74 14.45 0.08 0.96
10 1.43 9.68 0.12 0.93 1.31 10.85 0.14 0.86
Mean 2.57 17.93 0.14 0.92 3.01 19.58 0.14 0.91
Stdev 0.51 3.98 0.03 0.03 0.94 4.27 0.03 0.04
Training Validation
57 
 
 
Table 3.11: Model 3 training/validation for 12-step ahead prediction modeling. Results are 
for two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
12 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 6.54 32.59 0.22 0.75 9.34 31.88 0.22 0.83
1b 6.51 33.78 0.20 0.81 6.86 41.15 0.24 0.77
2a 6.44 27.53 0.22 0.85 8.10 29.27 0.19 0.86
2b 6.99 34.57 0.28 0.83 8.68 32.05 0.20 0.82
3a 5.87 25.84 0.30 0.70 9.60 35.03 0.31 0.68
3b 5.44 24.52 0.25 0.73 7.62 31.25 0.27 0.74
4a 7.63 41.16 0.26 0.81 7.93 43.94 0.29 0.84
4b 6.08 30.72 0.18 0.85 5.54 34.04 0.23 0.83
5 4.16 23.83 0.20 0.67 4.70 26.31 0.23 0.63
6 5.37 27.64 0.21 0.76 5.81 32.62 0.23 0.63
7 6.96 34.67 0.25 0.89 7.54 40.06 0.30 0.82
8 6.82 36.78 0.27 0.83 8.52 36.96 0.22 0.75
9 5.18 31.16 0.18 0.86 3.33 24.37 0.14 0.88
10 3.60 16.91 0.20 0.81 3.05 16.64 0.21 0.69
Mean 5.97 30.12 0.23 0.80 6.90 32.54 0.23 0.77
Stdev 1.13 6.23 0.04 0.06 2.11 7.13 0.05 0.08
Training Validation
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Table 3.12: Model 3 training/validation for 18-step ahead prediction modeling. Results are 
for two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
18 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 10.16 42.36 0.28 0.57 14.52 44.26 0.30 0.67
1b 10.37 45.75 0.28 0.66 11.24 54.29 0.31 0.62
2a 10.69 38.80 0.32 0.70 12.72 39.65 0.26 0.77
2b 11.36 45.97 0.36 0.71 14.36 41.95 0.27 0.74
3a 8.32 29.68 0.33 0.57 13.50 44.64 0.39 0.46
3b 8.08 30.05 0.30 0.58 11.027 38.68 0.34 0.63
4a 11.29 53.57 0.35 0.69 11.39 59.89 0.42 0.71
4b 9.67 41.66 0.26 0.73 9.83 45.44 0.32 0.70
5 6.18 29.89 0.24 0.50 6.99 33.36 0.29 0.42
6 7.77 34.65 0.26 0.62 8.15 42.87 0.30 0.36
7 11.10 45.61 0.34 0.82 11.73 52.85 0.39 0.68
8 10.04 45.17 0.33 0.73 12.78 46.52 0.28 0.61
9 8.18 41.73 0.24 0.76 4.54 32.40 0.18 0.80
10 6.06 23.24 0.27 0.66 5.18 19.62 0.24 0.56
Mean 9.23 39.15 0.30 0.66 10.57 42.60 0.30 0.62
Stdev 1.80 8.46 0.04 0.09 3.23 10.05 0.06 0.13
Training Validation
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Table 3.13: Model 3 training/validation for 36-step ahead prediction modeling. Results for 
two weeks of data divided into one week of training and one week of validation. AE and AAE 
values are presented in mg/dL. *Modeling results for Subject 10 are for one week of data that was 
divided into three days of training and four days of validation. 
 
  
36 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1a 18.40 55.74 0.36 0.22 24.42 68.32 0.47 0.28
1b 19.01 68.29 0.42 0.22 21.52 82.98 0.49 0.14
2a 21.30 61.75 0.53 0.30 22.77 60.45 0.40 0.52
2b 20.02 64.54 0.49 0.42 27.31 63.84 0.43 0.44
3a 13.99 37.43 0.41 0.24 21.61 61.05 0.52 0.01
3b 13.17 40.73 0.41 0.27 17.43 53.65 0.49 0.33
4a 17.87 71.84 0.52 0.50 16.83 90.99 0.67 0.40
4b 20.09 65.30 0.41 0.38 16.06 65.54 0.54 0.39
5 9.46 39.32 0.33 0.16 10.69 41.34 0.35 0.09
6 11.64 44.34 0.33 0.37 11.04 54.03 0.38 -0.02
7 23.53 67.78 0.50 0.60 28.40 83.98 0.62 0.23
8 17.01 60.02 0.43 0.52 22.56 64.57 0.37 0.21
9 13.87 59.22 0.32 0.59 3.98 51.02 0.28 0.54
10 14.12 37.78 0.44 0.15 13.63 26.23 0.30 0.20
Mean 16.68 55.29 0.42 0.35 18.45 62.00 0.45 0.27
Stdev 4.04 12.64 0.07 0.15 6.94 17.08 0.11 0.18
Training Validation
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3.11 APPENDIX 3.3: Training/Validation/Testing Model 2 k-SAP Tables 
Table 3.14: Model 2 training/validation/testing for 1-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing.  AE and AAE values are presented in mg/dL. 
 
 
Table 3.15: Model 2 training/validation/testing for 6-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing.  AE and AAE values are presented in mg/dL. 
 
1 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a -0.01 4.28 0.03 0.99 -0.44 4.23 0.03 1.00 -0.72 4.00 0.03 1.00
1b -0.03 4.14 0.03 1.00 0.08 3.95 0.02 1.00 0.05 5.47 0.03 1.00
2a -0.04 4.04 0.03 0.99 0.31 5.20 0.03 0.99 0.24 4.18 0.02 0.99
2b 0.03 4.02 0.03 1.00 0.34 4.15 0.03 0.99 0.07 4.15 0.03 1.00
3a -0.04 4.15 0.05 0.99 0.78 4.42 0.04 1.00 0.89 3.77 0.03 0.99
3b 0.00 3.09 0.03 1.00 0.33 6.08 0.05 0.98 0.10 4.55 0.05 0.99
4a -0.03 5.77 0.03 0.99 0.51 5.34 0.03 1.00 -0.36 6.18 0.04 0.99
4b 0.03 4.60 0.03 1.00 -0.22 5.25 0.03 0.99 -0.66 4.03 0.04 1.00
5 -0.02 2.33 0.02 1.00 0.01 2.14 0.02 1.00 -0.19 3.22 0.03 0.99
6 -0.04 4.73 0.04 0.99 0.23 5.22 0.04 0.99 0.32 5.03 0.04 0.98
7 0.03 5.81 0.04 1.00 -0.23 6.64 0.05 0.99 0.61 8.74 0.05 0.99
8 0.06 5.16 0.04 0.99 -0.14 5.06 0.03 0.99 -0.37 4.81 0.03 0.99
9 0.02 3.20 0.02 1.00 0.43 2.88 0.02 1.00 -0.01 3.07 0.02 1.00
Mean 0.00 4.26 0.03 0.99 0.15 4.66 0.03 0.99 0.00 4.71 0.03 0.99
Stdev 0.03 1.01 0.01 0.00 0.35 1.23 0.01 0.00 0.47 1.49 0.01 0.00
1 week Training 4 day Validation 3 day Test
6 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a -0.24 17.78 0.13 0.92 -3.93 18.89 0.14 0.94 -5.73 19.51 0.17 0.96
1b -0.27 17.80 0.11 0.95 0.80 17.98 0.10 0.94 0.49 24.15 0.16 0.93
2a -0.28 17.24 0.15 0.94 2.57 20.74 0.13 0.93 2.38 15.65 0.10 0.96
2b 0.18 20.06 0.18 0.94 3.38 16.93 0.13 0.89 0.71 16.94 0.13 0.96
3a -0.51 17.09 0.20 0.88 6.63 22.59 0.21 0.90 7.72 17.39 0.14 0.90
3b -0.08 14.86 0.16 0.90 3.39 22.29 0.18 0.83 0.85 18.44 0.19 0.90
4a -0.27 25.17 0.16 0.93 5.45 28.36 0.19 0.95 -3.77 23.13 0.16 0.94
4b 0.25 18.48 0.11 0.95 -1.87 22.85 0.14 0.91 -6.01 19.04 0.18 0.96
5 -0.16 12.93 0.11 0.89 0.06 12.63 0.11 0.93 -2.31 15.92 0.15 0.76
6 -0.42 18.34 0.15 0.90 2.00 22.74 0.16 0.82 1.72 18.21 0.13 0.84
7 0.48 22.71 0.17 0.96 -2.07 21.29 0.19 0.94 4.33 27.54 0.18 0.93
8 0.50 22.25 0.17 0.93 -1.25 23.39 0.15 0.89 -3.09 20.68 0.13 0.92
9 0.38 17.26 0.11 0.95 4.89 15.86 0.10 0.97 -0.09 13.98 0.08 0.93
Mean -0.03 18.61 0.15 0.93 1.54 20.50 0.15 0.91 -0.22 19.28 0.15 0.91
Stdev 0.35 3.28 0.03 0.03 3.23 4.02 0.04 0.04 3.94 3.79 0.03 0.06
3 day Test1 week Training 4 day Validation
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Table 3.16: Model 2 training/validation/testing for 12-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
 
Table 3.17: Model 2 training/validation/testing for 18-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
12 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a -0.74 24.44 0.17 0.86 -8.35 27.28 0.21 0.89 -10.38 31.81 0.29 0.91
1b -0.55 25.99 0.17 0.88 2.39 28.87 0.17 0.85 1.07 34.81 0.23 0.86
2a -0.79 27.09 0.25 0.86 5.39 29.50 0.20 0.86 5.06 23.90 0.15 0.91
2b 0.24 33.47 0.30 0.85 8.02 27.36 0.20 0.78 1.00 27.38 0.22 0.89
3a -1.14 24.46 0.30 0.74 12.47 36.68 0.34 0.73 14.43 24.86 0.20 0.80
3b -0.11 22.19 0.24 0.78 6.64 28.89 0.24 0.74 1.31 27.65 0.29 0.80
4a -0.33 40.38 0.29 0.82 12.25 49.65 0.37 0.86 -7.02 34.37 0.25 0.88
4b 0.25 29.42 0.19 0.88 -4.12 34.82 0.22 0.83 -13.30 33.38 0.34 0.88
5 -0.09 20.82 0.18 0.72 0.23 22.60 0.20 0.78 -5.00 23.17 0.23 0.49
6 -1.04 27.73 0.23 0.78 5.36 31.46 0.22 0.68 2.57 26.64 0.20 0.69
7 1.07 34.46 0.26 0.91 -5.11 32.09 0.30 0.87 7.80 42.31 0.27 0.85
8 0.54 32.65 0.25 0.86 -2.53 35.93 0.23 0.77 -6.56 31.21 0.20 0.83
9 1.41 30.48 0.19 0.87 11.23 27.94 0.16 0.91 0.07 22.77 0.12 0.81
Mean -0.10 28.74 0.23 0.83 3.37 31.78 0.24 0.81 -0.69 29.56 0.23 0.82
Stdev 0.79 5.50 0.05 0.06 6.92 6.65 0.06 0.07 7.64 5.73 0.06 0.11
1 week Training 4 day Validation 3 day Test
18 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a -0.79 27.93 0.20 0.82 -11.58 33.32 0.27 0.85 -13.26 40.71 0.37 0.85
1b -0.84 31.79 0.21 0.82 4.34 36.33 0.21 0.76 1.57 39.46 0.26 0.81
2a -1.13 33.84 0.34 0.78 8.25 36.38 0.25 0.81 7.29 31.38 0.20 0.85
2b 0.22 42.68 0.39 0.76 12.51 36.88 0.24 0.74 1.11 36.85 0.29 0.81
3a -1.58 26.99 0.33 0.67 16.75 44.08 0.40 0.60 19.40 30.09 0.23 0.71
3b -0.01 26.00 0.28 0.69 9.37 33.14 0.28 0.67 1.38 33.66 0.36 0.72
4a -0.14 50.46 0.38 0.73 17.17 67.49 0.52 0.75 -8.04 42.29 0.31 0.82
4b -0.43 38.12 0.25 0.81 -5.69 42.44 0.29 0.75 -21.17 45.45 0.49 0.78
5 0.19 23.41 0.21 0.62 0.57 27.70 0.24 0.65 -7.12 26.16 0.26 0.38
6 -1.56 32.34 0.27 0.70 8.42 37.73 0.26 0.51 2.72 31.39 0.24 0.55
7 1.14 42.57 0.33 0.86 -7.57 40.94 0.40 0.78 10.47 52.11 0.33 0.76
8 0.29 37.94 0.29 0.81 -4.71 43.32 0.27 0.69 -9.69 38.25 0.25 0.77
9 2.52 39.18 0.24 0.79 17.20 37.65 0.20 0.85 0.29 27.99 0.16 0.71
Mean -0.16 34.87 0.29 0.76 5.00 39.80 0.30 0.72 -1.16 36.60 0.29 0.73
Stdev 1.13 7.85 0.06 0.07 9.98 9.48 0.09 0.10 10.68 7.46 0.09 0.13
1 week Training 4 day Validation 3 day Test
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3.12 APPENDIX 3.4: Training/Validation/Testing Model 3 k-SAP Tables 
Table 3.18: Model 3 training/validation/testing for 1-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
 
Table 3.19: Model 3 training/validation/testing for 6-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
1 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a 0.28 3.50 0.02 0.99 0.40 2.90 0.02 1.00 0.23 2.49 0.02 1.00
1b 0.20 2.78 0.02 1.00 0.16 2.68 0.01 1.00 0.25 4.16 0.02 1.00
2a 0.19 2.80 0.02 1.00 0.22 3.83 0.02 1.00 0.31 2.94 0.02 1.00
2b 0.27 3.67 0.03 1.00 0.25 3.09 0.03 0.99 0.37 3.09 0.02 1.00
3a 0.32 3.81 0.05 0.99 0.49 3.87 0.04 1.00 0.49 3.25 0.03 1.00
3b 0.20 2.67 0.03 1.00 0.27 6.05 0.05 0.98 0.31 4.43 0.04 0.99
4a 0.33 5.65 0.03 0.99 0.44 5.06 0.03 1.00 0.10 6.06 0.04 0.99
4b 0.26 4.45 0.03 1.00 0.23 5.04 0.03 0.99 0.17 3.69 0.03 1.00
5 0.15 2.28 0.02 1.00 0.19 1.98 0.02 1.00 0.15 3.04 0.03 0.99
6 0.26 4.20 0.03 0.99 0.24 4.75 0.04 0.99 0.43 4.36 0.03 0.99
7 0.00 5.06 0.04 1.00 -0.10 6.13 0.05 0.99 0.67 8.13 0.05 0.99
8 0.32 4.64 0.03 1.00 0.33 4.62 0.03 1.00 0.39 4.22 0.03 1.00
9 0.19 3.15 0.02 1.00 0.22 2.70 0.02 1.00 0.10 3.04 0.02 1.00
Mean 0.23 3.74 0.03 1.00 0.26 4.05 0.03 0.99 0.30 4.07 0.03 0.99
Stdev 0.09 1.02 0.01 0.00 0.15 1.34 0.01 0.00 0.17 1.54 0.01 0.00
1 week Training 4 day Validation 3 day Test
6 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a 2.85 19.90 0.14 0.90 4.40 17.95 0.12 0.94 2.86 16.30 0.12 0.96
1b 2.64 18.91 0.11 0.94 2.05 18.46 0.10 0.94 3.14 27.32 0.17 0.91
2a 2.48 14.91 0.12 0.95 2.50 18.94 0.12 0.93 4.14 15.02 0.09 0.96
2b 2.88 20.12 0.17 0.94 2.95 13.76 0.14 0.89 4.09 13.76 0.10 0.97
3a 2.95 16.99 0.20 0.87 4.61 23.29 0.21 0.89 4.86 16.81 0.13 0.89
3b 2.44 14.84 0.15 0.91 3.18 24.41 0.19 0.80 4.05 18.81 0.19 0.89
4a 3.29 24.76 0.15 0.93 4.95 27.34 0.17 0.95 0.53 23.00 0.15 0.93
4b 2.53 18.38 0.11 0.95 2.41 23.03 0.13 0.90 1.55 16.78 0.14 0.96
5 1.86 13.53 0.11 0.89 2.43 12.99 0.11 0.93 1.88 16.81 0.16 0.75
6 2.37 17.19 0.13 0.91 2.30 23.07 0.16 0.82 2.99 18.08 0.13 0.85
7 2.92 21.11 0.15 0.96 1.99 22.99 0.18 0.92 7.38 27.39 0.17 0.93
8 3.20 23.48 0.17 0.93 3.37 24.37 0.15 0.89 4.20 20.37 0.13 0.92
9 2.14 17.20 0.10 0.95 2.26 14.43 0.09 0.97 1.01 14.48 0.08 0.92
Mean 2.66 18.56 0.14 0.92 3.03 20.39 0.14 0.90 3.28 18.84 0.13 0.91
Stdev 0.41 3.32 0.03 0.03 1.02 4.62 0.04 0.05 1.83 4.50 0.03 0.06
1 week Training 4 day Validation 3 day Test
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Table 3.20: Model 3 training/validation/testing for 12-step ahead prediction modeling. 
Results for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
 
Table 3.21: Model 3 training/validation/testing for 18-step ahead prediction modeling. 
Results are for two weeks of data divided into one week of training, four days of validation and 3 
days of testing. AE and AAE values are presented in mg/dL. 
 
  
12 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a 6.54 32.59 0.22 0.75 10.72 33.19 0.22 0.78 7.85 30.47 0.22 0.87
1b 6.51 33.78 0.20 0.81 5.61 35.56 0.19 0.77 7.74 45.09 0.27 0.78
2a 6.44 27.53 0.22 0.85 5.73 30.08 0.21 0.84 10.27 28.53 0.17 0.88
2b 6.99 34.57 0.28 0.83 7.67 23.71 0.23 0.73 9.83 23.72 0.16 0.91
3a 5.87 25.84 0.30 0.70 9.41 40.36 0.37 0.66 9.91 26.09 0.21 0.75
3b 5.44 24.52 0.25 0.73 6.99 33.99 0.27 0.68 8.46 27.61 0.27 0.78
4a 7.63 41.16 0.26 0.81 10.83 49.21 0.34 0.83 3.07 35.11 0.22 0.86
4b 6.08 30.72 0.18 0.85 6.29 37.53 0.22 0.78 4.52 29.24 0.25 0.88
5 4.16 23.83 0.20 0.67 5.02 25.71 0.21 0.72 4.32 27.03 0.25 0.39
6 5.37 27.64 0.21 0.76 5.99 34.97 0.23 0.64 5.59 29.59 0.22 0.62
7 6.96 34.67 0.25 0.89 3.17 37.59 0.31 0.80 15.99 44.86 0.27 0.82
8 6.82 36.78 0.27 0.83 7.79 40.76 0.25 0.71 9.52 31.80 0.19 0.81
9 5.18 31.16 0.18 0.86 4.37 24.29 0.15 0.91 1.88 24.47 0.13 0.77
Mean 6.15 31.14 0.23 0.80 6.89 34.38 0.25 0.76 7.61 31.05 0.22 0.78
Stdev 0.93 5.13 0.04 0.07 2.34 7.24 0.06 0.08 3.76 6.87 0.05 0.14
1 week Training 4 day Validation 3 day Test
18 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit AE AAE RAAE rfit
1a 10.16 42.36 0.28 0.57 16.58 45.34 0.30 0.58 12.26 43.09 0.31 0.74
1b 10.37 45.75 0.28 0.66 9.87 51.72 0.28 0.53 12.21 56.12 0.33 0.67
2a 10.69 38.80 0.32 0.70 9.21 38.17 0.27 0.77 15.88 40.98 0.25 0.78
2b 11.10 45.77 0.36 0.71 13.06 33.05 0.31 0.61 15.82 32.98 0.23 0.84
3a 8.32 29.68 0.33 0.57 13.05 51.41 0.47 0.43 14.25 33.29 0.26 0.58
3b 8.08 30.05 0.30 0.58 10.79 41.30 0.34 0.55 11.35 35.20 0.34 0.69
4a 11.29 53.57 0.35 0.69 13.89 69.15 0.51 0.69 7.14 44.09 0.27 0.76
4b 9.67 41.66 0.26 0.73 11.69 48.77 0.29 0.64 7.28 40.86 0.35 0.76
5 6.18 29.89 0.24 0.50 7.38 35.12 0.29 0.52 6.52 31.24 0.28 0.18
6 7.77 34.65 0.26 0.62 9.00 45.57 0.30 0.37 7.09 39.45 0.29 0.33
7 11.10 45.61 0.34 0.82 4.93 50.02 0.42 0.64 24.77 58.29 0.34 0.70
8 10.04 45.17 0.33 0.73 11.35 51.28 0.31 0.53 14.71 40.04 0.23 0.70
9 8.18 41.73 0.24 0.76 6.20 32.52 0.18 0.85 2.23 32.25 0.17 0.61
Mean 9.46 40.36 0.30 0.66 10.54 45.65 0.33 0.59 11.65 40.60 0.28 0.64
Stdev 1.59 7.39 0.04 0.09 3.26 10.00 0.09 0.13 5.77 8.52 0.05 0.19
1 week Training 4 day Validation 3 day Test
64 
 
 
CHAPTER 4.  Modeling the Simultaneous Effects of Food, Activity, 
Stress and Their Interactions on Blood Glucose Concentration in Type 1 
Diabetic Subjects 
A paper to be submitted to Diabetes Technology 
 
Kaylee Kotz1, Ali Cinar2, Elizabeth Littlejohn3, Laurie Quinn4  
and Derrick K. Rollins, Sr. 1,5*  
 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, 
2Department of Chemical and Biological Engineering, Illinois Institute of Technology, 
Chicago, IL, 3Institute for Endocrine Discovery and Clinical Care, Chicago, IL, 4College 
of Nursing, University of Illinois at Chicago, Chicago, IL, 5Department of Statistics, 
Iowa State University, Ames, IA 
 
*Corresponding Author 
 
4.1 ABSTRACT 
Due to recent advances in biomedical technology, such as automatic insulin delivery 
systems using glucose sensors and insulin pumps, blood glucose modeling and control 
has received considerable attention in the process control community and models of 
various degrees of complexity have been developed.  Glucose levels are affected by many 
variables, such as stress, physical activity, hormonal changes, periods of growth, 
medications, illness/infection, fatigue, as well as food intake and insulin tolerance.  
Furthermore, not only does glucose change from several disturbances but their impact on 
blood glucose level is highly correlated, dynamic and nonlinear making it difficult to 
distinguish the effect each input has on blood glucose.  Thus, the objective of this work is 
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to expand on the modeling work presented in Kotz et al.1 to take into account the 
simultaneous and multiple effects of food, activity, stress and their interactions.  This 
paper will present second order interaction modeling results for 15 Type 1 diabetic 
subjects where thirteen variables (i.e., three food variables, seven activity variables, basal 
insulin, bolus insulin, and time of day (TOD)) were collected for two weeks and modeled 
using the Wiener block-oriented method of Rollins et al.2.  Results are given to show the 
importance of interactions between input variables for k-steps ahead prediction (k-SAP) 
from 5 minutes to 1.5 hours into the future.  
 
4.2 INTRODUCTION 
Disturbances such as stress, physical activity, hormonal changes, periods of growth, 
medications, illness/infection and fatigue can cause large changes in glucose levels for 
individuals with Type 1 diabetes.  Their effects on blood glucose concentration are highly 
complex and highly correlated.  In a normal person, several systems, such as the 
metabolic, endocrine, and cardiovascular systems function collectively to maintain 
homeostasis.  However, in a diabetic person their inherent glucose regulation mechanism 
becomes dysfunctional.   If the amount of carbohydrates in a meal was the only 
disturbance to blood glucose level, management would be easy.  However, not only are 
there other disturbances in food, such as fats and proteins, but also in the levels and types 
of activities as well as physical and emotional stress.  Furthermore, not only does glucose 
change from several sources of disturbances but their impact on glucose level is highly 
correlated, dynamic and nonlinear making it difficult to distinguish the effect each input 
has on blood glucose. For example, a study by Wahren et al.3 demonstrated that an 
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individual’s blood glucose response to moderate exercise can vary based on the pre-
exercise metabolic ketotic state of the individual.  Results of this study showed that for an 
individual who was ketotic (resting ketone levels >3mmol/L) prior to exercising 
experienced a steady increase in arterial blood glucose concentration as the duration of 
exercise increased.  On the other hand, individuals who were non-ketotic (resting ketone 
levels <1.1 mmol/L) prior to exercising experienced a steady decrease in arterial blood 
glucose concentration as the duration of exercise increased.   
 
The study by Wahren et al.3 illustrates that it is imperative to account for the interactions 
between activity and metabolic state variables’ and that there is strong need for input 
measurements that can provide information such as activity and meals, as well as models 
that can explicitly deal with interactions.  The purpose of this article is to expand on the 
modeling work of Kotz et al.1 and to test the effectiveness of the modeling methodology 
presented in Rollins et al.2 to infer blood glucose by taking into account the simultaneous 
and multiple effects of food, activity, stress, circadian rhythm and their interactions.   
 
4.3 MODELING METHODOLGY 
The modeling approach used in this work is an expansion of the Wiener modeling 
method used by Kotz et al.1 to include input interactions.  A block diagram with p inputs 
and one output is given in Figure 4.2. 
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Figure 4.1: Block diagram for a general Wiener network with p inputs and one output. Each 
input, xi, is passed though their own linear dynamic block, Gi(s), after which they are collected 
and passed through a single nonlinear static gain function, f(V), to produce the output, y. 
 
The inputs, xi, of the Wiener network are the measured noninvasive variables or 
disturbances (i.e., food, activity, and stress) and the output, y, is blood glucose 
concentration.  Each input has its own linear dynamic block, Gi, and each dynamic block 
has an intermediate unobservable, output vi.  All the intermediate vi’s are collected and 
passed through a nonlinear static gain block,  f(V), to produce the final output, y.  
Although the xi’s can be highly correlated, the vi’s are not likely to be correlated since 
each input is not likely to have similar dynamic behavior; e.g., even though carbohydrates 
and fats are likely to be highly correlated since they both appear at the time of food 
consumption, they have different residence times (i.e., follow different pathways in 
converting to glucose) in blood and hence different dynamic behavior.  The linear 
dynamic blocks has been found to be approximated well by a second-order-plus-lead with 
dead time (SOPLDT) form as shown in Eq. (4.1)1,2. 
G1
G2
Gp
f (V)
x1
x2
xp
v2
v1
V y
vp
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  (4.1) 
where i = 1, . . ., p, p is the total number of inputs, τi is the time constant for input i, ζi is 
the damping coefficient, τai is the lead parameter and θi is the dead time.  As shown by 
Rollins et al.6 the approximate discrete-time form of Eq. (4.1) can be written as:   
  (4.2) 
where, to satisfy the unity gain constraint, 𝜔𝜔2,𝑖 = 1 − 𝛿𝛿1,𝑖 − 𝛿𝛿2,𝑖 − 𝜔𝜔1,𝑖 and  
  (4.3) 
  (4.4) 
  (4.5) 
After obtaining an Eq. (4.2) for each i, the modeled glucose value is determined by 
substituting these results into the second order linear regression form, including 
interaction terms, of the nonlinear static block function, f (V).    
  (4.6) 
  
where a, b, and c, denote the linear, quadratic and interaction parameters, respectively, 
for i = 1, . . ., p.  Thus, the complete input-only model for measured blood glucose 
concentration including the error term in additive “white” noise, is 
  (4.7) 
𝜏𝜏𝑖𝑖
2 𝑑𝑑2𝑣𝑣𝑖𝑖(𝑡𝑡)
𝑑𝑑𝑡𝑡2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖 𝑑𝑑𝑣𝑣𝑖𝑖(𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝑣𝑣𝑖𝑖(𝑡𝑡) = 𝜏𝜏𝑎𝑎𝑖𝑖 𝑑𝑑𝑥𝑥𝑖𝑖(𝑡𝑡 − 𝜃𝜃𝑖𝑖)𝑑𝑑𝑡𝑡 + 𝑥𝑥𝑖𝑖(𝑡𝑡 − 𝜃𝜃𝑖𝑖) 
𝑣𝑣𝑖𝑖 ,𝑡𝑡 = 𝛿𝛿1,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−∆𝑡𝑡 + 𝛿𝛿2,𝑖𝑖𝑣𝑣𝑖𝑖 ,𝑡𝑡−2∆𝑡𝑡 + 𝜔𝜔1,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−(∆𝑡𝑡−𝜃𝜃) + 𝜔𝜔2,𝑖𝑖𝑥𝑥𝑖𝑖 ,𝑡𝑡−(2∆𝑡𝑡−𝜃𝜃) 
𝛿𝛿1,𝑖𝑖 = 2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝛿𝛿2,𝑖𝑖 = −𝜏𝜏𝑖𝑖2𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜔𝜔1,𝑖𝑖 = (𝜏𝜏𝑎𝑎𝑖𝑖 + Δ𝑡𝑡)Δ𝑡𝑡𝜏𝜏𝑖𝑖2 + 2𝜏𝜏𝑖𝑖𝜏𝜏𝑖𝑖Δ𝑡𝑡 + Δ𝑡𝑡2 
𝜂𝜂𝑡𝑡 = 𝑓𝑓(𝐕𝐕) = 𝑎𝑎0 + 𝑎𝑎1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡 + 𝑏𝑏1𝑣𝑣1,𝑡𝑡2 + ⋯+ 𝑏𝑏𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡2  +𝑐𝑐1,2𝑣𝑣1,𝑡𝑡𝑣𝑣2,𝑡𝑡 + ⋯+ 𝑐𝑐𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1,𝑡𝑡𝑣𝑣𝑝𝑝 ,𝑡𝑡  
𝑦𝑦𝑡𝑡 = 𝜂𝜂𝑡𝑡 + 𝑒𝑒𝑡𝑡  
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where yt is the modeled blood glucose concentration at time t, et is the error term under 
the assumptions of independence, normality and constant variance (i.e., 𝑒𝑒𝑡~𝑁𝑁(0,𝜎𝜎2)  ∀𝑡𝑡).  
Under these assumptions Rollins et al.6 proposed the following input-only model 
estimator for the true value of glucose concentration to be 
  (4.8) 
  
 
4.4 THE STUDY 
In an Institutional Review Board (IRB) approved study, the subjects followed a two week 
free-living protocol outlined in Kotz et al.1.  In this study the iProTM Continuous Glucose 
Monitor (Medtronic MiniMed, Inc., Northridge, California) was used to provide 
continuous glucose measurements, activity information was collected using the 
SenseWear® Pro3 Body Monitoring System (BodyMedia Inc., Pittsburgh, Pennsylvania) 
shown in Figure 4.3 and no constraints were placed on the subjects daily diet or lifestyle.  
In addition, the subject’s insulin pumps were downloaded to retrieve their daily bolus and 
basal insulin infusion rates. 
 
Figure 4.2: BodyMedia, Inc. SenseWear® Pro3 Body Monitoring System. 
𝑦𝑦�𝑡𝑡 = ?̂?𝜂𝑡𝑡 = 𝑎𝑎�0 + 𝑎𝑎�1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡 + 𝑏𝑏�1𝑣𝑣1,𝑡𝑡2 + ⋯+ 𝑏𝑏�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡2  +?̂?𝑐1,2𝑣𝑣1,𝑡𝑡𝑣𝑣2,𝑡𝑡 + ⋯+ ?̂?𝑐𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1,𝑡𝑡𝑣𝑣𝑝𝑝 ,𝑡𝑡  
Timestamp Button
2-axis Accelerometer 
(inside)
Heat Flux Sensor
Near-Body Temperature
GSR Sensors
Skin Temperature
AAA Battery, USB connector 
and wireless inside
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Food information was collected two ways during this study: (1) subjects recorded the 
approximate serving size and the time they started eating for all of the food they 
consumed into a PDA, which used Weightmania® Pro software (Edward A. Greenwood, 
Inc., Cambridge, Massachusetts) to determine the carbohydrate, fat, and protein content 
of their meals; and (2) the subjects followed a timestamping protocol, which used the 
timestamp feature on the SenseWear® armband, to indicate the approximate size of the 
meal and the time they started eating.   
 
The objective of this modeling problem is to maximize the true but unknown correlation 
coefficient between the observed and fitted glucose concentrations, which is defined as 
𝜌𝑦,𝑦�  and estimated by rfit.  Under this objective a model is useful only when the true 
model fit is greater than zero (i.e., 𝜌𝑦,𝑦� > 0).  As described in Rollins et al.6, due to the 
highly complex mapping of the parameters into the response space of rfit, the following 
indirect criterion is used 
  (4.9) 
  
where Θ is a vector representing the estimated dynamic and static parameters, ζi, τi, τai, 
and θi, for all i.  To determine whether interactions are beneficial when modeling blood 
glucose concentration in Type 1 Diabetics a goal was set for rfit to be greater than 0.60, 
which was the average validation rfit  value found by Kotz et al.1 for 14 Type 1 diabetics 
using the linear form of Eq. (4.8).  Therefore, this work seeks to identify a linear model 
𝑀𝑀𝑎𝑎𝑥𝑥𝑖𝑖𝑚𝑚𝑖𝑖𝑧𝑧𝑒𝑒 𝑟𝑟𝑓𝑓𝑖𝑖𝑡𝑡  𝑏𝑏𝑦𝑦 𝑀𝑀𝑖𝑖𝑛𝑛𝑖𝑖𝑚𝑚𝑖𝑖𝑧𝑧𝑖𝑖𝑛𝑛𝑔𝑔     𝑆𝑆𝑆𝑆𝐸𝐸Θ = � (𝑦𝑦1 − 𝑦𝑦�𝑡𝑡)2𝑛𝑛Δ𝑡𝑡
𝑡𝑡=Δ𝑡𝑡  
 𝑆𝑆𝑢𝑢𝑏𝑏𝑗𝑗𝑒𝑒𝑐𝑐𝑡𝑡 𝑡𝑡𝑜𝑜:                                         𝜏𝜏𝑖𝑖 > 0,  𝜏𝜏𝑖𝑖 > 0,  𝜃𝜃𝑖𝑖 ≥ 0   ∀𝑖𝑖 
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with interactions in Eq. (4.10) to infer blood glucose concentration that results in a 
sufficiently large value of rfit.   
        (4.10)  
This goal of this study was to obtain the best model that gave similar results in the two 
sequential data sets: training, validation.  Data in the training set is used directly in fitting 
the model under the objective criterion to minimize SSE. The validation set is used to 
protect against over fitting and is used to restrict improvements in the training set to those 
that provide similar improvements in the validation set. Parameter estimation in this 
study was done using the Excel® Solver Routine.   
 
While correlation is one method used in this study for assessing the usefulness of the 
model, absolute error (AE), average absolute error (AAE) and relative average absolute 
error (RAAE) are also used to assess the fit of the model.  The AE is simply the average 
of the residuals.  
  (4.11) 
where n is the number of observed blood glucose measurements.  To prove that the 
aforementioned convergence criterion was met the AE value should equal 0.0 mg/dL.  
The AAE of a model is:  
  (4.12) 
?̂?𝜂𝑡𝑡 = 𝑓𝑓(𝐕𝐕) = 𝑎𝑎�0 + 𝑎𝑎�1𝑣𝑣1,𝑡𝑡 + ⋯+ 𝑎𝑎�𝑝𝑝𝑣𝑣𝑝𝑝 ,𝑡𝑡 + ?̂?𝑐1,2𝑣𝑣1,𝑡𝑡𝑣𝑣2,𝑡𝑡 + ⋯+ ?̂?𝑐𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1,𝑡𝑡𝑣𝑣𝑝𝑝 ,𝑡𝑡  
𝐴𝐴𝐸𝐸 = 1
𝑛𝑛
�(𝑦𝑦𝑖𝑖 − 𝑦𝑦�𝑖𝑖)𝑛𝑛
𝑖𝑖=1  
𝐴𝐴𝐴𝐴𝐸𝐸 = 1
𝑛𝑛
�|𝑦𝑦𝑖𝑖 − 𝑦𝑦�𝑖𝑖 |𝑛𝑛
𝑖𝑖=1  
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In addition to sufficiently large rfit values for both the training and validation sets an 
acceptable model must also have a relatively small AAE that is close to zero.  
Consequently, accuracy is expected to increase as AAE decreases.   
 
To scale the variability in blood glucose concentration between subjects the RAAE is a 
statistic used and tends to be a better judge of model accuracy than the AAE.  The RAAE 
of a model is:  
  (4.13) 
where 𝜎𝜎� = � 1
𝑛−1
∑ (𝑦𝑦𝑖 − 𝑦𝑦�𝑖)2𝑛𝑖=1 .  Like AAE an acceptable model must have a relatively 
small RAAE and the accuracy of a model is expected to increase as RAAE decreases.  
Kotz et al.1 determined the average RAAE for 14 Type 1 diabetics using the linear form 
of Eq. (4.8) for the validation set to be roughly 0.40, this result will be used as a 
benchmark for determining model performance in this study.   
 
4.5 RESULTS AND DISCUSSION 
The results presented are modeling results under Eq. (4.10) for two weeks of data 
collection, with the exception of Subject 14 and Subject 15, where one week was used for 
training the model and one week was used for model validation.  Modeling results for 
Subject 14 are for a week of data that was divided into three days of training and four 
days of validation. For Subject 15 the modeling results presented are for three days of 
data that was divided into two days of training and one day of validation.   
 
𝑅𝑅𝐴𝐴𝐴𝐴𝐸𝐸 =  𝐴𝐴𝐴𝐴𝐸𝐸
𝜎𝜎�
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Table 4.1: Modeling values for input-only interaction model on training and validation sets. 
Results are for two weeks of data divided into one week of training and one week of validation. 
AE and AAE values are presented in mg/dL. *Modeling results for Subject 14 are for one week 
of data that was divided into three days of training and four days of validation. **Modeling 
results for Subject 15 are for three days of data that was divided into two days of training and one 
day of validation. 
 
 
Table 4.1 shows that for all subjects the training AE value was close or equal to 0.0 
mg/dL, validating the convergence criterion.  The average AAE value in all cases was 
approximately 40.4 mg/dL and 46.6 mg/dL in training and validation, respectively, with 
bias in the validation set attributing the slight difference between the two sets.  Evidence 
of this bias is seen in the mean AE value of 4.4 mg/dL.  The amount of bias in the 
validation set is subject specific and is shown to give AE values as small as -0.1 mg/dL 
for Subject 12 to as large as -56 mg/dL for Subject 8. The average RAAE values for the 
training and validation sets are 0.33 and 0.38, respectively, which are only slightly better 
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1 0.00 33.47 0.23 0.73 -27.06 46.58 0.44 0.82
2 0.00 46.50 0.30 0.60 15.29 45.67 0.29 0.75
3 0.00 38.58 0.37 0.72 12.54 42.83 0.31 0.76
4 0.00 39.05 0.36 0.77 40.44 49.80 0.33 0.76
5 0.00 29.69 0.34 0.59 36.31 47.98 0.38 0.62
6 0.00 32.45 0.36 0.43 10.84 42.60 0.42 0.53
7 0.00 60.06 0.45 0.61 18.25 70.51 0.48 0.62
8 0.00 48.76 0.33 0.67 -55.98 71.99 0.68 0.62
9 0.00 24.36 0.22 0.61 -0.44 26.77 0.24 0.59
10 0.00 43.05 0.34 0.46 10.95 36.77 0.26 0.45
11 0.00 63.05 0.52 0.64 -19.49 55.43 0.55 0.72
12 0.00 48.03 0.37 0.68 -0.10 49.35 0.33 0.66
13 0.01 48.69 0.31 0.69 20.26 44.27 0.23 0.72
14* 0.02 22.36 0.29 0.64 6.93 18.32 0.23 0.60
15** 0.00 28.28 0.24 0.85 -2.28 52.53 0.57 0.87
Mean 0.00 40.43 0.33 0.64 4.43 46.76 0.38 0.67
Stdev 0.01 12.25 0.08 0.11 24.39 13.82 0.14 0.11
Training Validation
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than the target of 0.4.  However, note that the validation RAAE value is ≤ 0.4 for nine 
subjects.  Average training and validation rfit values are 0.64 and 0.67, respectively, 
which is at close to the target of 0.6.  
 
Figure 4.3 includes plots of Subject 8 one week validation set for: (a) model fit with only 
linear terms and (b) model fit with linear and interaction terms.  Figure 4.3 illustrates the 
improvement in model accuracy with the addition of interactions to the model.  The 
model appears to be capturing more of the swings that the subject is experiencing.  
 
 
Figure 4.3: Subject 8 linear and interaction model comparison. Results are shown for a week 
of validation. (a) Model fit with only linear terms. (b) Model fit with linear and interaction terms.  
 
To assess the contribution of interactions for modeling Type 1 diabetes, Table 4.2 
presents the percent contribution of the linear and interaction terms the final reduced 
Model 1.  The percent contribution of the interactions for the reduced Model 1 was 
calculated using  
  (4.14) 
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where Cinteractions and Clinear are the average contribution of the interaction and linear 
terms, respectively.  The contribution for the interactions is determined by 
  (4.15) 
The percent contribution of the interaction terms for all the subjects averaged 
approximately 33.5%.  As seen in Table 4.2 the amount interactions contribute to the 
model is subject specific and is shown to vary from as little as 18.5% for Subject 7 to as 
much as 53.3% for Subject 10.   
Table 4.2: Percent contribution of interaction terms in input-only model. 
 
 
 
 
 
 
𝐶𝐶𝑖𝑖𝑛𝑛𝑡𝑡𝑒𝑒𝑟𝑟𝑎𝑎𝑐𝑐𝑡𝑡𝑖𝑖𝑜𝑜𝑛𝑛𝑠𝑠 = �𝛽𝛽1,2𝑣𝑣1𝑣𝑣2 + ⋯+ 𝛽𝛽𝑝𝑝−1,𝑝𝑝𝑣𝑣𝑝𝑝−1𝑣𝑣𝑝𝑝� 
Subject Linear Interactions
1 65.84 34.16
2 75.52 24.48
3 64.65 35.35
4 68.03 31.97
5 55.28 44.72
6 71.98 28.02
7 81.51 18.49
8 58.01 41.99
9 57.91 42.09
10 46.71 53.29
11 66.52 33.48
12 68.58 31.42
13 76.93 23.07
14* 67.50 32.50
15** 72.04 27.96
Mean 66.47 33.53
Stdev 9.07 9.07
% Contribution
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4.6 CONCLUDING REMARKS 
The convergence criterion outlined in the study section of this paper was met.  Results 
showed that the reduced nonlinear static model with interactions generated average 
RAAE and rfit values comparable to those found by Kotz et al1 for 14 Type 1 diabetics 
using a reduced nonlinear static model without interactions.  However, on a case to case 
basis the interaction model generally proved to outperform the reduced nonlinear static 
model.  It was also shown that interactions make a large contribution to the final overall 
model performance.  Based on this research, a reduced nonlinear static interaction model 
and the interaction Model are the recommended models for modeling and predicting 
blood glucose concentration in Type 1 diabetes, respectively.  
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4.9 APPENDIX 4.1:  Input-only Interaction Model k-SAP Tables  
Table 4.3: Input-only interaction model on training and validation sets 1-step ahead 
prediction modeling. Results include interactions for two weeks of data divided into one week of 
training and one week of validation. AE and AAE values are presented in mg/dL. *Modeling 
results for Subject 14 are for one week of data that was divided into three days of training and 
four days of validation. **Modeling results for Subject 15 are for three days of data that was 
divided into two days of training and one day of validation.  
 
1 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1 0.02 4.60 0.03 0.99 -0.69 4.38 0.03 1.00
2 -0.01 4.38 0.03 0.99 0.20 4.82 0.03 1.00
3 -0.09 4.32 0.04 0.99 0.34 5.09 0.03 0.99
4 -0.01 4.07 0.03 1.00 0.76 4.66 0.03 1.00
5 -0.03 4.17 0.05 0.99 0.95 4.31 0.04 0.99
6 0.00 3.55 0.04 0.99 0.28 5.44 0.05 0.99
7 0.02 6.14 0.04 0.99 0.29 6.06 0.04 1.00
8 0.04 5.21 0.03 1.00 -0.80 5.49 0.04 0.99
9 -0.03 2.38 0.02 1.00 -0.01 2.63 0.02 0.99
10 -0.07 4.84 0.04 0.99 0.24 5.41 0.04 0.98
11 0.02 6.46 0.05 0.99 0.00 8.00 0.06 0.99
12 0.06 4.95 0.03 1.00 -0.03 5.02 0.03 0.99
13 0.01 3.22 0.02 1.00 0.23 2.89 0.02 1.00
14* -0.01 2.73 0.04 0.99 0.12 2.90 0.04 0.99
15** 0.04 5.00 0.04 0.99 -0.15 6.44 0.05 0.99
Mean 0.00 4.40 0.03 0.99 0.11 4.90 0.04 0.99
Stdev 0.04 1.13 0.01 0.00 0.45 1.42 0.01 0.00
Training Validation
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Table 4.4: Input-only interaction model on training and validation sets for 6-step ahead 
prediction modeling. Results include interactions for two weeks of data divided into one week of 
training and one week of validation. AE and AAE values are presented in mg/dL. *Modeling 
results for Subject 14 are for one week of data that was divided into three days of training and 
four days of validation. **Modeling results for Subject 15 are for three days of data that was 
divided into two days of training and one day of validation. 
 
6 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1 0.06 18.37 0.13 0.92 -4.96 18.32 0.14 0.96
2 -0.07 19.50 0.12 0.93 1.79 21.29 0.13 0.94
3 -0.57 18.48 0.16 0.93 2.67 20.24 0.13 0.93
4 -0.11 18.78 0.16 0.94 7.26 20.18 0.13 0.93
5 -0.44 17.06 0.20 0.88 7.98 21.86 0.19 0.89
6 -0.05 16.01 0.17 0.88 2.41 19.99 0.18 0.88
7 0.03 26.12 0.17 0.93 2.99 27.10 0.18 0.94
8 0.19 19.98 0.13 0.95 -7.11 23.84 0.19 0.93
9 -0.22 13.14 0.11 0.89 0.00 14.21 0.13 0.88
10 -0.70 18.78 0.15 0.90 1.69 21.89 0.16 0.82
11 0.45 25.61 0.20 0.95 -0.30 26.72 0.23 0.93
12 0.45 22.90 0.17 0.93 -0.10 23.06 0.15 0.91
13 0.18 16.80 0.10 0.95 2.60 14.27 0.08 0.96
14* -0.13 10.73 0.14 0.92 1.05 10.54 0.14 0.87
15** 0.01 20.78 0.18 0.92 -1.14 27.67 0.28 0.95
Mean -0.06 18.87 0.15 0.92 1.12 20.75 0.16 0.91
Stdev 0.33 4.09 0.03 0.02 3.87 4.91 0.05 0.04
Training Validation
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Table 4.5: Input-only interaction model on training and validation sets for 12-step ahead 
prediction modeling. Results include interactions for two weeks of data divided into one week of 
training and one week of validation. AE and AAE values are presented in mg/dL. *Modeling 
results for Subject 14 are for one week of data that was divided into three days of training and 
four days of validation. **Modeling results for Subject 15 are for three days of data that was 
divided into two days of training and one day of validation. 
 
12 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1 -0.19 26.03 0.18 0.84 -10.09 27.26 0.23 0.91
2 -0.13 28.42 0.18 0.86 4.18 30.36 0.19 0.88
3 -1.24 28.23 0.26 0.85 4.98 29.14 0.20 0.88
4 -0.24 29.39 0.26 0.87 16.56 31.25 0.21 0.86
5 -1.04 23.35 0.28 0.76 13.79 34.07 0.30 0.74
6 -0.06 22.72 0.24 0.77 4.35 27.30 0.25 0.81
7 0.22 40.80 0.29 0.82 7.22 43.48 0.30 0.87
8 0.19 31.03 0.20 0.88 -14.59 37.80 0.32 0.83
9 -0.20 20.70 0.18 0.72 -0.04 22.48 0.20 0.72
10 -1.59 28.39 0.23 0.78 3.89 30.48 0.21 0.67
11 0.95 37.82 0.30 0.89 -1.53 39.69 0.36 0.86
12 0.38 33.73 0.26 0.85 0.00 34.80 0.23 0.81
13 0.76 29.27 0.18 0.88 5.93 23.75 0.13 0.89
14* -0.13 16.47 0.22 0.83 2.31 14.48 0.19 0.74
15** -0.22 26.77 0.23 0.86 -1.65 42.44 0.46 0.91
Mean -0.17 28.21 0.23 0.83 2.35 31.25 0.25 0.82
Stdev 0.69 6.25 0.04 0.05 7.88 7.84 0.08 0.08
Training Validation
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Table 4.6: Input-only interaction model on training and validation sets for 18-step ahead 
prediction modeling. Results include interactions for two weeks of data divided into one week of 
training and one week of validation. AE and AAE values are presented in mg/dL. *Modeling 
results for Subject 14 are for one week of data that was divided into three days of training and 
four days of validation. **Modeling results for Subject 15 are for three days of data that was 
divided into two days of training and one day of validation. 
 
 
 
 
 
 
  
18 SAP
Subject AE AAE RAAE rfit AE AAE RAAE rfit
1 0.08 29.97 0.21 0.78 -14.15 33.01 0.29 0.89
2 -0.50 33.83 0.21 0.79 6.54 35.83 0.22 0.82
3 -1.63 33.61 0.32 0.80 6.84 34.85 0.25 0.83
4 -0.37 34.82 0.31 0.82 24.99 38.75 0.26 0.81
5 -1.43 24.74 0.29 0.71 17.29 40.02 0.35 0.64
6 -0.01 26.12 0.28 0.68 6.03 31.98 0.30 0.74
7 0.53 50.26 0.37 0.74 10.70 55.14 0.40 0.79
8 -0.17 37.30 0.25 0.82 -20.32 46.77 0.42 0.75
9 0.00 23.00 0.20 0.63 0.12 25.89 0.23 0.62
10 -2.06 33.12 0.27 0.70 5.54 35.85 0.25 0.53
11 0.90 44.78 0.37 0.85 -2.56 50.14 0.47 0.78
12 0.11 39.20 0.30 0.79 -0.39 40.82 0.26 0.74
13 1.27 37.64 0.23 0.81 9.08 30.30 0.16 0.83
14* -0.12 19.06 0.25 0.75 4.10 15.65 0.20 0.68
15** -0.62 28.17 0.25 0.84 -2.32 49.51 0.54 0.89
Mean -0.27 33.04 0.27 0.77 3.43 37.63 0.31 0.76
Stdev 0.90 8.29 0.05 0.06 11.16 10.17 0.11 0.10
Training Validation
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CHAPTER 5.  CONCLUSIONS 
5.1 SUMMARY 
In the first study outlined in Chapter 3 the convergence criterion was met and the set of 
model parameters found through the optimization process proved to be effective in 
maintain a stable model throughout the training, validation, and test sets.  Results showed 
that the reduced nonlinear static model generated rfit values significantly greater than 
those found for 20 Type 2 diabetics.  It is believed that this significant increase in model 
performance can be attributed to the inclusion of insulin in the model.  It should be noted 
that there was little difference in model performance as it relates to the reduction food 
information from the detailed food logging protocol to the armband timestamping 
protocol.  The first study also presented a compelling case for the inclusion of the 
armband in glucose modeling for Type 1 diabetics.  It was shown that the reduction of 
food information that occurred during the timestamping protocol was more often made up 
for by the armband rather than insulin or time of day.  The final portion of this first study 
examined the value of the proposed modeling approach for k-SAP and showed its ability 
to effectively correct for model bias for a short time into the future.   
 
The convergence criterion was also met in the second study which was outlined in 
Chapter 4.  Results showed that the reduced nonlinear static model with interactions 
generated average RAAE and rfit values comparable to those found in the first study.  
However, on a case to case basis the interaction model generally proved to outperform 
the reduced nonlinear static model.  It was also shown that interactions make a large 
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contribution to the final overall model performance.  Based on this research, a reduced 
nonlinear static interaction model is the recommended model for modeling and predicting 
blood glucose concentration in Type 1 diabetes, respectively.  
 
5.2 FUTURE WORKS 
The models developed in this research will serve as the baseline for future research in 
Type 1 diabetes.  Several potentially fruitful directions for this research include: 
1. Improving and expanding the model by incorporating glucose.  It is known 
that there is a strong interaction between glucose and insulin since insulin is the 
major contributing factor to the reduction of glucose in the bloodstream.  
Currently the model approach presented in this research fails to take this into 
account.  
2. Developing an automatic modeling scheme.  A manual method is currently 
being used to determine model parameters.  In order to model a larger number of 
cases in a shorter amount of time it would be beneficial to have an automatic 
modeling scheme that can determine model parameters that allow for equal or 
better model performance than the current manual method.  
3. Explore other options for obtaining food information.  Currently subjects are 
asked to keep either a detailed food log or to timestamp for meals, which is time 
consuming and undesirable.  Many subjects already enter the number of 
carbohydrates they are consuming into insulin pumps; the carbohydrate wizard 
function determines the appropriate bolus insulin amount to deliver based on a 
subject specified ratio. Since many subjects are already using this insulin pump 
83 
 
 
feature it may be prove to improve the accuracy of the food information collected 
on the subjects.   
Finally, since the reduction food information from the detailed food logging procedure to 
the armband timestamping procedure had little impact modeling performance for the four 
subjects that completed both food logging protocols, more timestamping cases should be 
run to more accurately rule in the favor of one procedure over the other.   
 
